[
    {
        "pmid": "40818936",
        "title": "\"The association of cardiometabolic diseases and related medications with cognitive performance: a cross-sectional observational study from Central Poland\".",
        "abstract": "Global ageing rising prevalence cardiometabolic disease dementia becomes increasingly important public health topic relation evoked extensive research effort aimed finding link cardiovascular health cognitive decline Cardiometabolic medications widely prescribed beneficial effect vascular health closely examined potential influence cognitive health capacity modify risk dementia crosssectional study 1735 individual Central Poland investigated cardiometabolic diseases treatments cognitive function Cognitive performance evaluated using MiniMental State Examination MMSE dichotomized ≥ 24 point  24 points logistic regression revealed strong association age OR107 95 CI 105108 p  0001 stroke OR143 95 CI 130184 p  0001 worse MMSE dichotomized score Similarly insulin usage linked increased risk low MMSE OR133 95CI 106173 p  0008 contrast BMI OR096 95CI 094098 p  0001 lipid disorder OR069 95 CI 048092 p  001 use calcium channel blocker OR071 95 CI 048094 p  004 alphablocker OR054 95 CI 023086 p  0004 angiotensin II receptor antagonist OR 056 95 CI 029083 p  0001 associated normal cognitive function Rsup2sup  008 p  0001 result present complex connection cardiometabolic disorders treatment cognitive functioning research highlight necessity tailored approach prescribing cardiovascular medications considering potential link cognitive health Especially role angiotensin II receptor antagonist merit studies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818936/",
        "source_type": "Global"
    },
    {
        "pmid": "40818851",
        "title": "Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.",
        "abstract": "pharmacological therapy shown certainty improve cardiovascular prognosis patient kidney failure chronic haemodialysis aimed investigate effect steroidal mineralocorticoid receptor antagonist spironolactone cardiovascular outcome patient haemodialysis high risk cardiovascular events ALCHEMIST investigatorinitiated multicentre doubleblind randomised placebocontrolled eventdriven trial conducted 64 university hospitals general hospitals nonprofit private practice dialysis centre France Belgium Monaco Adult patient aged 18 year older kidney failure chronic haemodialysis least one cardiovascular comorbidity risk factor enrolled 4week runin period openlabel oral spironolactone 25 mg every day Participants randomly assigned 11 oral spironolactone titrated 25 mg per day placebo randomisation sequence computer generated stratified centre block 4 6 permutation treatment within block random assignment doubleblinded primary endpoint time first major adverse cardiovascular event cardiovascular death nonfatal myocardial infarction acute coronary syndrome stroke hospitalisation heart failure analysed intentiontotreat population also performed updated metaanalysis doubleblind randomised controlled trial mineralocorticoid receptor antagonist patient haemodialysis incorporating data ALCHEMIST study registered ClinicalTrialsgov NCT01848639 June 13 2013 Nov 24 2020 1442 patient locally screened eligibility 823 patient included trial 794 entered runin period 644 patient randomly assigned spironolactone n320 placebo n324 444 69 patient men 200 31 women trial stopped prematurely due lack funding sponsor Median followup 32·6 month IQR 17·348·4 primary endpoint occurred 78 24 320 patient spironolactone group 10·66 per 100 patientyears 95 CI 8·5413·31 79 24 324 patient placebo group 10·70 per 100 patientyears 8·5913·35 hazard ratio HR 1·00 95 CI 0·731·36 p0·98 Hyperkalaemia 6 mmolL reported 135 42 patient spironolactone group 134 41 placebo group HR 1·12 95 CI 0·881·43 metaanalysis mineralocorticoid receptor antagonist reduce allcause cardiovascular mortality nonfatal cardiovascular event increase odds hyperkalaemia event serum potassium concentration 6 mmolL patient kidney failure haemodialysis high risk adverse cardiovascular outcomes spironolactone reduce incidence major cardiovascular events updated metaanalysis show mineralocorticoid receptor antagonist reduce allcause cardiovascular mortality Therefore offlabel use spironolactone setting supported available evidence French Ministry Health",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818851/",
        "source_type": "Global"
    },
    {
        "pmid": "40818772",
        "title": "Mortality Outcomes and ACE Inhibitor Use in Patients with Idiopathic Pulmonary Fibrosis.",
        "abstract": "ACE inhibitor ACEi widely used antihypertensive agent proven cardioprotective effects Previous mechanistic clinical study suggested ACEi therapy may slow disease progression reduce mortality idiopathic pulmonary fibrosis IPF ACEi use associate reduced allcause realworld population IPF patients so association also present COPD patients retrospective analysis conducted using electronic health record Clinical Practice Research Datalink CPRD GOLD database 2019 linked HES Admitted Patient Care ONS death registration data Patients IPF COPD stratified based ACEi use defined ≥3 prescription within five year preceding diagnosis matched age gender smoking history using propensity score matching Multivariable Cox regression analysis performed adjusting age gender body mass index smoking status index multiple deprivation diabetes mellitus chronic kidney disease common cardiovascular comorbidities IPF cohort competing risk analysis used account causespecific mortality study included 3579 patient IPF matched COPD control mean age 74 years 36 female Among IPF cohort 1326 37 ACEi users compared 1061 30 amongst COPD patients ACEi use associated improved survival independent coexisting comorbidities IPF patient HR  089 95 CI  081098 p  0013 similar association found COPD patient HR  109 95 CI  095125 p  0234 ACEi therapy independently associated reduced allcause mortality IPF COPD Prospective trial warranted confirm finding IPF populations",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818772/",
        "source_type": "Global"
    },
    {
        "pmid": "40818766",
        "title": "Rationale, design and baseline characteristics of the multicENter, randomized, open-label, parallel group, study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients (ENVAD-HF).",
        "abstract": "notable improvement longterm survival hemocompatibilityrelated events heart failure HF emerging leading cause death contemporary left ventricular assist device LVAD population prospective randomized controlled trial RCTs investigated use HF therapy LVAD recipients observational data suggest benefit neurohormonal blockers especially achieving blood pressure BP target associated improved outcomes ENVADHF investigatorinitiated prospective multicenter randomized openlabel parallel group pilot study HeartMate 3 HM3 LVAD recipient evaluate safety tolerability insight efficacy sacubitrilvalsartan compared standard care SOC managing BP Medically stable LVAD recipient recent HM3 implantation ambulatory followup eligible participation randomized 11 receive sacubitrilvalsartan SOC used treating BP titrated aiming mean arterial pressure MAP goal 7590 mmHg 12month followup primary endpoint designed assess safety efficacy sacubitrilvalsartan compared SOC composite freedom allcause death deterioration renal function hyperkalemia symptomatic hypotension occurrence primary endpoint assessed first three month overall duration trial 12 months endpoint include clinical patientreported outcomes biomarker echocardiography assessment followup ENVADHF enrolled 60 patient February 2021 March 2024 17 females mean age 57±12 years 67 ambulatory followup 55 ischemic etiology 25 receiving LVAD destination therapy mean baseline MAP 87±7 mmHg median NTproBNP 2552 15953543 pgmL ENVADHF first prospective RCT pharmacological therapy management BP stable HM3 LVAD recipient achieving target enrolment provide data safety tolerability insight efficacy sacubitrilvalsartan versus SOC used treating BP",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818766/",
        "source_type": "Global"
    },
    {
        "pmid": "40818651",
        "title": "Impact of Sodium-glucose Cotransporter 2 Inhibitor on Recurrence and Cardiovascular Outcomes after Catheter Ablation for Atrial Fibrillation in Patients with Chronic Kidney Disease.",
        "abstract": "effect sodiumglucose cotransporter 2 inhibitor SGLT2i atrial fibrillation AF recurrence catheter ablation patient chronic kidney disease CKD remains uncertain investigate whether SGLT2i associated reduced risk AF recurrence catheter ablation CKD patients prospective ChineseAF Registry identified 628 AF patient CKD receiving initial catheter ablation January 2019 December 2023 Patients stratified SGLT2i group n119 nonSGLT2i group n509 based discharge prescriptions Propensity scorederived overlap weighting OW employed balance baseline characteristics primary outcome AF recurrence threemonth blanking period mean followup duration 131 ± 53 months patient SGLT2i group lower rate AF recurrence compared nonSGLT2i group OW adjustment 218 26119 v 312 159509 adjusted HR 056 95 CI 032098 P  0044 Additionally SGLT2i group demonstrated substantially lower rate composite outcome cardiovascular mortality cardiovascular hospitalization thrombotic events adjusted HR 038 95 CI 020073 P  0004 substantial reduction observed cardiovascular hospitalization adjusted HR 033 95 CI 016068 P  0002 SGLT2i treatment associated reduced risk AF recurrence composite outcome cardiovascular mortality cardiovascular hospitalization thrombotic events CKD patient receiving catheter ablation AF",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818651/",
        "source_type": "Global"
    },
    {
        "pmid": "40818367",
        "title": "Ex vivo calcium imaging of sympathetic neurons in intact mouse stellate ganglia.",
        "abstract": "Sympathetic hyperactivity common feature cardiovascular disease including hypertension sympathetic neuron hyperactive week angiotensin II AngII hypertension Nerve firing increase intracellular Casup2sup wanted develop Casup2sup imaging method quantify activity across many neuron once describe method ex vivo Casup2sup imaging intact mouse stellate ganglia imaged ganglion control AngII 700 ngminKg hypertensive mouse determine could identify Casup2sup parameter reflected hyperactivity expressed GCaMP6s tyrosine hydroxylase THpositive neuron THsupGCaMP6ssup Male female THsupGCaMP6ssup mouse 1725 week old used Images obtained baseline conditions stimulation nicotine 10 μM stimulation potassium chloride KCl 40 mM positive control GCaMP6s expression Differential fluorescence response quantified using opensource MATLAB processing tool additional MATLAB script composed analyze characterize feature fluorescent responses peak Casup2sup response nicotine treatment trended higher left right stellates AngIItreated mice distribution peak response differed significantly left ganglia Decay time similar groups compared peak Casup2sup response nicotine treatment vs KCl found altered frequency distribution nicotine KCl response left right stellates AngII mice raising possibility selective modulation cholinergic responses Calcium imaging allowed simultaneous analysis multiple cell within ganglia recapitulate bilateral hyperactivity identified electrophysiology",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818367/",
        "source_type": "Global"
    },
    {
        "pmid": "40818322",
        "title": "Mitocytosis-inducing nanoparticles alleviate gemcitabine resistance via dual disruption of pyrimidine synthesis and redox homeostasis in pancreatic ductal adenocarcinoma.",
        "abstract": "Metabolic reprogramming pancreatic ductal adenocarcinoma PDAC pose significant challenge efficacy gemcitabinebased chemotherapy Aberrant activation intracellular pyrimidine metabolism key factor contributing reduced effectiveness gemcitabine Combining gemcitabine metabolic regulator targeting critical pathway may alleviate gemcitabine resistance study focus abnormal activation dihydroorotate dehydrogenase DHODH PDAC cells pivotal enzyme de novo pyrimidine synthesis pathway diminishes cellular sensitivity gemcitabine catalyzes reduction ubiquinone ubiquinol playing essential role maintaining cellular redox homeostasis address challenges developed GE11 peptidemodified polyphenoliron chelate nanoparticles codelivery long carbon chainmodified gemcitabine DHODH inhibitor leflunomide peptide modification enabling nanoparticles target PDAC cell high expression epidermal growth factor receptor nanoparticles demonstrated ability induce mitocytosis achieve deep tumor penetration PDAC tissues Upon drug release core lesion three components modified gemcitabine leflunomide iron ion synergistically enhanced tumor cell killing alleviating gemcitabine resistance disrupting cellular redox homeostasis induce multimodal cell death situ pancreatic cancer mouse model strategy exhibited superior antitumor efficacy compared standard AG chemotherapy regimen nabpaclitaxel gemcitabine even 63fold lower gemcitabine concentration finding underscore potential approach highly effective therapeutic strategy PDAC treatment",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818322/",
        "source_type": "Global"
    },
    {
        "pmid": "40818264",
        "title": "IL-1 Pathway Inhibition in Recurrent Pericarditis Management: Real-World Adoption of Corticosteroid Sparing in RESONANCE.",
        "abstract": "Recurrent pericarditis RP guideline recommend secondline corticosteroid aspirinnonsteroidal antiinflammatory drugscolchicine complication protracted use underscore importance corticosteroidsparing strategies Given clinical trial evidence supporting interleukin IL1 pathway inhibition US Food Drug Administration approval rilonacept RP objective assess temporal trend corticosteroidsparing treatment RP multicenter registry RESONANCE REgiStry NAtural history recurreNt periCarditis pEdiatric adult patients NCT04687358 combine retrospective prospective data clinical practice single observation period Patients receiving treatment idiopathic postprocedural RP included Demographics treatment intensification quantified 313 patient aspirinnonsteroidal antiinflammatory drugscolchicine treatment median disease duration 19 years 1 preenrollment recurrence 44 n  138 intensified treatment rilonacept approval RP 71 n  10 patient intensified corticosteroid secondline therapy 29 n  4 intensified IL1 pathway inhibition rilonacept approval proportion patient intensifying secondline IL1 pathway inhibition increased 64 2023 n  27 rilonacept 57 anakinra 7 whereas proportion patient intensifying corticosteroid decreased 33 n  14 P  002 Approximately 59 n  35 secondline corticosteroid initiator later transitioned IL1 pathway inhibition patient starting secondline IL1 pathway inhibition 5 n  3 rilonacept 25 n  4 anakinra subsequently used corticosteroid 30 days RESONANCE IL1 pathway inhibition increasingly replaced corticosteroid secondline therapy patient starting corticosteroid transitioned IL1 pathway inhibition transitioned secondline IL1 pathway inhibition longterm corticosteroids finding may inform treatment algorithm patientprovider decisionmaking",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818264/",
        "source_type": "Global"
    },
    {
        "pmid": "40818181",
        "title": "Canagliflozin inhibits hepatic stellate cells activation and proliferation by inhibiting PP2A-mediated β-catenin dephosphorylation to attenuate hepatic fibrosis.",
        "abstract": "Hepatic fibrosis HF leading cause death worldwide yet currently safe effective treatment available Canagliflozin novel glucoselowering drug shown improve nonalcoholic steatohepatitis NASH However therapeutic effect HF underlying molecular mechanism remain unclear study HF induced mouse via intraperitoneal injection CClsub4sub Additionally immortalized hepatic stellate cell HSCs including HSCT6 LX2 cells used vitro experiments finding revealed Canagliflozin inhibited activation proliferation HSCs thereby downregulated expression level fibrotic marker αSMA Collagen I ultimately alleviating HF investigation demonstrated Canagliflozin inhibits protein phosphatase 2 PP2A activity HSCs turn prevents PP2Amediated dephosphorylation βcatenin attenuates Wntβcatenin signaling Wntβcatenin signaling considered key mechanism promote activation proliferation HSCs also crucial pathway development HF Moreover increased activity PP2A found promote expression fibrotic marker αSMA Collagen I HSCs conclusion study indicates Canagliflozin ameliorate HF via inhibiting PP2Amediated dephosphorylation βcatenin HSCs inhibition PP2A HSCs may represent potential therapeutic target cancer treatment also management HF",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818181/",
        "source_type": "Global"
    },
    {
        "pmid": "40818069",
        "title": "Cost-Effectiveness and Cost-Utility Analysis of Tongxinluo Capsules Compared With Conventional Therapy for the Treatment of Acute Myocardial Infarction.",
        "abstract": "Tongxinluo TXL capsule traditional Chinese medicine compound proven effective acute myocardial infarction AMI costeffectiveness unclear economic evaluation utilized individual data clinical trial compare major adverse cardiac cerebrovascular event MACCEs 30 day qualityadjusted life year QALYs 1 year intervention group TXL combined conventional therapy control group placebo plus conventional therapy healthcare perspective lifetime costutility analysis CUA conducted using Markov model sensitivity analysis performed evaluate robustness results total 3777 patient TXL 1889 placebo 1888 included analysis 30day total cost TXL placebo group ¥38561 5399 ¥39217 5490 respectively showing statistical difference 30day MACCEs rate 339 TXL group 524 placebo group p  0006 indicating TXLs superiority effectiveness 30 days lifetime TXL group incurred higher total cost ¥97108 13595 vs ¥92033 12885 gained QALYs 670 vs 630 incremental costeffectiveness ratio TXL ¥12421QALY 1739 1 Gross Domestic Product per capital threshold ¥89358 12510 2023 China Sensitivity analysis confirmed robust results revealing TXL likely accepted placebo willingness pay exceeds ¥12500 1739 TXL costeffective option compared placebo AMI",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40818069/",
        "source_type": "Global"
    },
    {
        "pmid": "40817904",
        "title": "South Asian Representation in Cardiovascular Disease Randomized Controlled Trials: A Systematic Review.",
        "abstract": "One 4 individual worldwide South Asian ancestry therefore increased risk cardiovascular disease CVD However South Asian representation CVD randomized controlled trial RCTs well known aim systematic review measure South Asian representation CVD RCTs extract postrandomization primary outcome estimate population conducted systematic review identify major CVD RCTs published 2018 2022 study manually screened reviewed identify South Asian participant representation rates protocol systematic review prospectively registered PROSPERO South Asian Representation Cardiovascular Clinical Trials CRD42023396522 included 310 RCTs representing 1036737 total 32764 32 South Asian participants South Asian participant 754 enrolled trial South Asia 652 enrolled single trial India excluding trial South Asian individual represented 11 total trial participants South Asian representation highest trial studying coronary artery disease 90 whereas South Asian individual identified trial studying heart failure cardiac arrest valvular heart disease Postrandomization data available 28197 South Asian individuals representing 73 participant postrandomization data South Asian individual underrepresented major CVD RCTs effort extend enrollment initiative RCTs South Asian individual urgently needed extent underrepresentation driver elevated cardiovascular disease risk merit study",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40817904/",
        "source_type": "Global"
    },
    {
        "pmid": "40817236",
        "title": "MicroRNA-4516 in extracellular vesicles-derived mesenchymal stem cells suppressed integrin αV-mediated lung fibrosis.",
        "abstract": "Idiopathic pulmonary fibrosis IPF characterized recruitment lung fibroblast site within lung interstitium along differentiation myofibroblasts induced transforming growth factor TGFβ1 mediator fibrosis which turn lead accelerated contractile lung fibrotic process excessive extracellular matrix ECM deposition Extracellular vesicle EVs small particle released cell contain physiologically active substances including messenger RNAs microRNAs miRNAs proteins Although EVs derived mesenchymal stem cell MSCs expected promising drug various intractable diseases including IPF underlying mechanism remain elusive study aimed elucidate mechanism underlying effect MSCEVs lung fibroblastmediated antifibrotic processes ability TGFβ1stimulated lung fibroblast migrate toward fibronectin contract threedimensional type collagen gel evaluated Using miRNA array aimed identify miRNAs associated fibrotic mechanism MSCEVs Furthermore effect MSCEVs analyzed mouse model bleomycin BLMinduced lung fibrosis including resulting histopathology degree fibrosis downstream signaling pathways Administration MSCEVs resulted significant suppression TGFβ1stimulated collagen gel contraction migration expression αsmooth muscle actin ECM Upon treatment MSCEVs lung fibroblast derived fibrotic lung showed greater inhibition response normal lung fibroblasts effect mediated via integrin αVmediated focal adhesion kinase signaling MAPK pathway including JNK p38MAPK andor ERK12 signaling miR4516 identified MSCEVs human lung fibroblasts recapitulated effects Administration MSCEVs resulted significant accumulation attenuation BLMinduced fibrotic lung tissue along reduced expression integrin αV lung interstitium Collectively finding study indicate MSCEVs may represent promising novel therapeutic strategy address pulmonary fibroblastmediated mechanism lung fibrosis",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40817236/",
        "source_type": "Global"
    },
    {
        "pmid": "40816899",
        "title": "Utilization of telemedicine in the care of children with obesity.",
        "abstract": "Obesity chronic relapsing progressive disease increasing prevalence significantly impact health quality life even children associated increased risk metabolic cardiovascular disease insulin resistance type 2 diabetes mellitus hypertension dyslipidemia metabolic dysfunctionassociated steatotic liver disease Additionally obesity lead development sleep apnea syndrome orthopedic issues psychological complications cornerstone care educating whole family healthy lifestyle however may often challenging due obstacle time constraints limited access specialists low longterm adherence families Telemedicine offer innovative approach improving obesity treatment child digital tools online consultations smart applications wearable technologies enables effective monitoring dietary physical activity habits support mental health reduces time financial burden families Studies indicate combining inperson remote support along active involvement family members lead higher success rate weight reduction healthy lifestyle maintenance article focus use telemedicine treatment obesity children providing overview method applied field effectiveness context current scientific knowledge",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40816899/",
        "source_type": "Global"
    },
    {
        "pmid": "40816891",
        "title": "Dyslipidemias as rare diseases.",
        "abstract": "Dyslipidemias mostly considered disease mass incidence However also several dyslipidemias occur within framework rare diseases genetically determined review focused three selected disease new therapy available significantly change prognosis patients Homozygous familial hypercholesterolaemia associated extreme elevation LDL cholesterol leading premature manifestation atherosclerotic cardiovascular disease first decade life Thanks new hypolipidemic drug evinacumab lomitapide patient today much better prognosis past Lipodystrophies heterogeneous group disease characterized progressive loss adipose tissue leading metabolic abnormalities Due new causal metreleptine therapy help patient managing metabolic complication significantly Familial chylomicronemia associated increased risk atherosclerotic cardiovascular disease accompanied extremely high level triglycerides leading frequent attack acute pancreatitis potentially fatal Therapy volanesorsen lead reduction hypertriglyceridemia thereby reducing risk developing acute pancreatitis Although disease rare necessary think diagnose early Interdisciplinary cooperation essential search treatment patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40816891/",
        "source_type": "Global"
    },
    {
        "pmid": "40816766",
        "title": "<i>miR-153</i> prevents NRF2 nuclear translocation to drive hypoperfusion-related cognitive deficits by targeting <i>KPNA5</i>.",
        "abstract": "imiRNAibased therapeutic represent promising approach treating multiple diseases yet key regulatory imiRNAsi chronic cerebral hypoperfusion CCHrelated cognitive impairment remains unclear Here identify imiR153i consistently upregulated male female mild cognitive impairment MCI latestage Alzheimers disease AD patients well basal forebrain male female postmortem AD specimen male CCH rats Knockdown imiR153i basal forebrain alleviated CCHinduced cognitive deficits Mechanistically imiR153i directly targeted Karyopherin alpha 5 KPNA5 nuclear transport protein facilitates nuclear factor erythroid 2related factor 2 NRF2 nuclear translocation imiR153i suppressed iKPNA5i via two binding site 3UTR impairing NRF2mediated antioxidant response promoting oxidative stress KPNA5 bound three nuclear localization sequence NRF2 protein interaction Restoration imiR153iKPNA5NRF2 axis basal forebrain alleviated oxidative stress damage male CCH rats effect observed hippocampus finding reveal potential role imiR153iKPNA5NRF2 axis CCHrelated cognitive declinebSignificance Statementb Impairment basal forebrain recognized early event pathogenesis Alzheimers disease AD patients iMicroRNAsi imiRNAsi emerged promising therapeutic candidate disease involving complex pathological processes study reveal critical role imiR153i AD progression uncover novel mechanism underlying chronic cerebral hypoperfusion CCHinduced cognitive decline basal forebrain rats demonstrate imiR153i negatively regulates KPNA5 expression basal forebrain thereby inhibiting nuclear translocation NRF2 promoting oxidative stressinduced neuronal damage finding identify imiR153i potential therapeutic target CCHassociated cognitive impairment and notably provide first evidence implicating KPNA5 pathophysiology neurodegenerative diseases",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40816766/",
        "source_type": "Global"
    },
    {
        "pmid": "40816584",
        "title": "A systematic review and meta-analysis of randomized controlled trials on the efficacy and safety of Tanshinone IIA sodium sulfonate injection as adjunctive therapy for stroke.",
        "abstract": "Tanshinone IIA core ingredient Salvia miltiorrhiza Bge effect blood circulation promotion blood stasis removement widely used cardiovascular cerebrovascular disease treatment adjunctive therapy Stroke remains leading cause disability death posing serious public health threat Tanshinone IIA sodium sulfonate injection STS derived Salvia miltiorrhiza Bge Danshen widely used China adjunctive therapy ischemic stroke However clinical efficacy safety remain uncertain metaanalysis aim evaluate efficacy safety STS treating ischemic stroke focusing effect blood circulation biomarkers metaanalysis conducted based PICOS framework incorporating randomized controlled trial RCTs comprehensive literature search across eight database performed updated February 2024 RCTs screened using defined search strategy inclusion criteria quality included trial independently assessed two investigator following Cochrane Handbook version 510 Metaanalyses performed using RevMan 53 publication bias assessed Stata 170 Twentytwo trial involving 2289 participant included pooled result showed STS significantly improved effective rate reduced NIHSS STS also decreased whole blood viscosity including lowshear highshear plasma viscosityand lowered red cell aggregation index day 7 14 Additionally reduced level total cholesterol TC triglyceride TG lowdensity lipoprotein cholesterol LDLC Ddimer Dr fibrinogen Fib hematocrit HCT Pselectin S100B neuronspecific enolase NSE 14 days Ddimer level remained significantly lower STS also increased highdensity lipoprotein cholesterol HDLC cerebral blood flow marker Vm Qm mean blood pressure MBP However significant difference found activity daily living ADL compared conventional treatment evidence publication bias analysis effective rate adverse effects Tanshinone IIA sodium sulfonate injection appears relatively safe neuroprotective agent adjunctive use ischemic stroke associated improved NIHSS score beneficial change hemorheology lipid profiles cerebral blood flow coagulation parameters serum biomarkers S100B Pselectin NSE PROSPERO CRD4202024093",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40816584/",
        "source_type": "Global"
    },
    {
        "pmid": "40815499",
        "title": "Lactylation in Cardiovascular Diseases: Epigenetic Mechanisms and Therapeutic Potential.",
        "abstract": "global burden mortality largely attributable cardiovascular disease CVDs altered metabolic homeostasis play critical role identification lactylation epigenetic modification mediated lactate transformed conventional view glycolysis byproduct mere metabolic intermediate multifaceted signaling molecule review comprehensively reveals mechanistic insight underlying lactylation CVDs particularly myocardial ischemia atherosclerosis heart failure highlighting pivotal role disease pathogenesis modulation transcriptional regulation metabolic adaptation cellular differentiation Considering enzymeregulated reversibility lactylation work systematically evaluates druggable targets thereby establishing conceptual foundation combined metabolismepigenetic therapeutics",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815499/",
        "source_type": "Global"
    },
    {
        "pmid": "40815470",
        "title": "Paeoniflorin improves atherosclerosis by regulating the gut microbiota and fecal metabolites.",
        "abstract": "Atherosclerosis AS chronic inflammatory disease key factor cardiovascular disease Paeoniflorin PF monomer component extracted red white paeony roots used prevention treatment cardiovascular diseases specific mechanism remains unclear ApoEsupsup mouse fed highfat diet randomly divided model group PF treatment group positive control group control group fed nonhighfat diet mouse PF group treated 100 mgkg PF100 50 mgkg PF50 25 mgkg PF25 PF gavage positive control group administered 10 mgkg atorvastatin calcium tablet gavage 8 week gavage PF delayed weight gain reduced elevated level serum total cholesterol triglycerides lowdensity lipoprotein cholesterol ApoEsupsup mice induced highfat diet Concomitantly PF alleviated aortic plaque formation downregulated TLR4 NFκB expression term underlying mechanism PF altered linoleic acid metabolism tryptophan metabolism steroid biosynthesis well improved abnormality galactose metabolism glycerophospholipid metabolism metabolic pathways Moreover PF restored dysbiosis Firmicutes Bacteroidota Actinobacteriota Finally increased abundance iLactobacillusi iBifidobacteriumi beneficial bacteria result suggest PF improves highfat dietinduced alleviates highfat dietinduced intestinal barrier damage moreover antiatherosclerotic effect may related improvement intestinal metabolic disorder altered abundance microbiotabIMPORTANCEbAtherosclerosis AS chronic progressive disease mainly characterized vascular endothelial cell damage inflammation lipid deposition Inflammatory immunerelated mechanism play key role occurrence development AS study showed paeoniflorin improve blood lipid levels reduce arterial inflammation restore intestinal permeability regulate metabolites increase abundance beneficial flora alleviate occurrence AS Thus finding may contribute understanding traditional Chinese medicine exerts holistic effect modulating microbiotametabolite axis",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815470/",
        "source_type": "Global"
    },
    {
        "pmid": "40815361",
        "title": "Efficacy analysis of intraventricular/intrathecal polymyxin B sulphate injections in the treatment of Post-neurosurgical CNS infections in neurocritical ill patients: a prospective observational study.",
        "abstract": "Intracranial infection due carbapenemresistant organism CRO pose substantial challenge neurosurgical intensive care unit NICU increasing prevalence infection caused carbapenemresistant Acinetobacter CRAB carbapenemresistant Klebsiella pneumoniae CRKP necessitates development novel treatment strategies prospective observational study aim evaluate efficacy safety intraventricularintrathecal polymyxin B sulfate PBS NICU patient neurosurgery enrolled patient diagnosed hospitalacquired postneurosurgical central nervous system CNS infection caused CRO Fudan Universityaffiliated Huashan Hospital January 2021 December 2023 Detailed information demographic characteristics course CRO infection treatment followup data recorded patient collected study Upon diagnosis external device immediately removed treatment regimen included local intraventricularintrathecal PBS injections systemic antibiotics cerebrospinal fluid CSF drainage Fisher exact test theχsup2sup test Student ttest used statistical analysis appropriate Among 27 patient included study 13 infected CRAB 14 CRKP mean age 494 ± 1654 years 963 patient undergone surgical procedure prior diagnosis 667 involved combined surgeries onset infection mean Glasgow Coma Scale GCS score 60 ± 217 average APACHE II score 173 ± 380 mean SOFA score 59 ± 220 total bacterial clearance rate CSF 815 2227 CRAB case achieving clearance rate 923 CRKP case achieving 714 p  0163 clinical cure rate 692 913 CRAB 642 914 CRKP Importantly mean duration onset CNS infection initiation intraventricularintrathecal injection 43 ± 501 days mean duration treatment 99 ± 392 days time achieve negative CSF culture averaged 106 ± 702 days significant difference found CRAB CRKP groups except variation sex ratio finding study verified efficacy safety intraventricularintrathecal PBS treating CROrelated intracranial infection neurosurgical patients combination local PBS administration systemic antibiotic therapy offer efficient treatment approach complex infections",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815361/",
        "source_type": "Global"
    },
    {
        "pmid": "40815096",
        "title": "Empowering Healthcare Professionals: Preventing Vascular Non-Communicable Diseases in the Transgender Community.",
        "abstract": " Introduction health disparity faced transgender genderdiverse TGD individual accessing healthcare particularly context noncommunicable disease NCDs cerebrovascular diseases significant public health concern paper highlight importance early identification NCDs cerebrovascular disease TGD populations emphasizing need culturally competent care comprehensive healthcare strategies Genderaffirming hormone therapy GHT play crucial role health transgender individuals Yet associated increased cardiovascular risk particularly among transgender female undergoing estrogen therapy Studies show higher prevalence hypertension hypercholesterolemia prediabetes smoking TGD population reinforcing need regular cardiovascular monitoring targeted preventive strategies Early identification NCDs cerebrovascular disease sign symptom essential mitigating longterm health complication improving patient outcomes Proactive screening timely intervention enhance quality life reduce healthcare disparities contribute costeffective care strategies Strengthening integration diagnostic tool promoting inclusive healthcare policy foster greater trust engagement transgender individual healthcare providers Overall paper underscore need inclusive healthcare policy practice address unique healthcare need TGD individuals improve health outcomes reduce disparity within vulnerable population",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40815096/",
        "source_type": "Global"
    },
    {
        "pmid": "40814909",
        "title": "RETRACTION: The Impact of Long-Term Antihypertensive Treatment on Wound Healing After Major Non-Cardiac Surgery in Patients With Cardiovascular Diseases: A Meta-Analysis.",
        "abstract": "Y Liu C Ma X Tang S Liu Y Jin The Impact LongTerm Antihypertensive Treatment Wound Healing Major NonCardiac Surgery Patients Cardiovascular Diseases MetaAnalysis International Wound Journal 21 no 4 2024 e14858 httpsdoiorg101111iwj14858 article published online 28 March 2024 Wiley Online Library httponlinelibrarywileycom retracted agreement journal Editor Chief Professor Keith Harding John Wiley  Sons Ltd Following investigation publisher party concluded article accepted solely basis compromised peer review process editor therefore decided retract article author respond notice regarding retraction",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814909/",
        "source_type": "Global"
    },
    {
        "pmid": "40814811",
        "title": "Doxorubicin-Induced Toxicity and Bisoprolol-Protective Efficacy for Cardiomyocytes Monitored by Scanning Electrochemical Microscopy.",
        "abstract": "Cardiotoxicity chemotherapy drug major adverse effect cancer chemotherapy strongly compromise therapeutic outcomes application cardioprotective agent effective strategy mitigate cardiotoxicity clinic However effect chemotherapeutic drug doses well efficacy cardioprotective agent function cardiomyocytes especially different stage cardiotoxicity well explored partly owing lack realtime functional parameter cardiomyocytes drug treatment Herein constructed iin vitroi doxorubicin DOXinduced cardiotoxicity DIC model culturing neonatal rat primary cardiomyocytes polyacrylamide PA gel stiffness around 200 kPa adding DOX different concentration mimic mild moderate severe stage chemotherapeutic druginduced cardiotoxicity used scanning electrochemical microscopy SECM monitor respiratory activity contraction frequency membrane permeability cardiomyocytes DOX treatment iin situi SECM result obtained demonstrated 02550 μM DOX dosage led decreased respiratory activity contraction frequency accompanied increased membrane permeability cardiomyocytes also used SECM evaluate cardioprotective effect bisoprolol a clinically approved βblocker cardiovascular diseases cardiomyocytes DOX treatment obtained optimal protective efficacy 10 μM DOXtreated cardiomyocytes work provides iin situi functional information living cardiomyocytes chemotherapeutic drug cardioprotective agent treatments contributing better understanding pathological feature prevention strategy chemotherapyinduced cardiotoxicity",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814811/",
        "source_type": "Global"
    },
    {
        "pmid": "40814613",
        "title": "Serum Syndecan-1 is Associated With Kidney and Cardiovascular Outcomes in Idiopathic Nephrotic Syndrome.",
        "abstract": "Idiopathic nephrotic syndrome INS associated important kidney cardiovascular morbidities tested hypothesis serum syndecan1 marker endothelial glycocalyx injury help identify patient risk unfavorable kidney cardiovascular outcomes included 348 child adult INS ini  35 unbiopsied ini  141 minimal change disease MCD ini  172 focal segmental glomerulosclerosis FSGS Nephrotic Syndrome Study Network NEPTUNE cohort 34 healthy participant ini  22 adults ini  12 children measured baseline serum syndecan1 level using enzymelinked immunosorbent assay evaluated relationship kidney cardiovascular outcomes performed iin vitroi study test whether INS serum different therapeutic may alter syndecan1 expression human glomerular endothelial cell GEnC Serum syndecan1 higher patient INS control high approximately onethird patient without proteinuria subnephrotic proteinuria Patients receiving steroids regardless disease activity showed higher syndecan1 immunosuppression Syndecan1 higher proteinuric patient MCD FSGS time serum collection syndecan1 modestly correlated proteinuria kidney function longitudinal analyses serum syndecan1 associated composite 40 decline kidney function kidney failure dyslipidemia Compared controls INS serum relapse increased syndecan1 expression cultured GEnC partially fully mitigated dexamethasone metalloprotease inhibitor added respectively culture media Baseline serum syndecan1 associated unfavorable kidney outcome cardiovascular risk factor INS",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814613/",
        "source_type": "Global"
    },
    {
        "pmid": "40814438",
        "title": "Chemical profiling of unpolished pigmented chakhao amubi rice produced lipid-lowering and cardioprotective effects via reducing oxidative stress and improving digestibility behaviour.",
        "abstract": "current research work designed study amylose content total phenolic content TPC total flavonoid content TFC total anthocyanin content TAC digestibility unpolished chakhao amubi CA rice extract along antioxidant antihyperlipidemic activity addition profiling bioactive polyphenolic compound present unpolished CA rice flour evaluated Based result obtained vitro antioxidant hypolipidemic activity rice extract CAEtOH ethanol selected vivo study Effect CAEtOH 45 day treatment evaluated highfathighsugar HFHS induced Wistar rats unpolished CA rice produce higher level TPC 34653 mg GAE100 g DW TFC 63422 mg QUE100 G DW TAC 87334 mg C3G100 g DW compared polished rice CAEtOH extract showed strong antioxidant activity lowest ICsub50sub value vitro antioxidant assays unpolished CA black rice extract exhibited significant HMG CoA reductase inhibitory activity Sinapic acid 62020 mg100 gm ocoumaric acid 20080 mg100 gm rosamarinic acid 19930 mg100 gm pcoumaric acid 15660 mg100 gm present abundantly fraction RDS SDS RS unpolished CA rice flour significantly different ipi  005 compared standard corn starch lower CAEtOH200 mgkg higher CAEtOH400 mgkg dos unpolished CA rice extract significantly p  0001 reduce body weight HFHS induced rats Oral administration unpolished CA rice extract reduced level TC TG LDLC VLDLC LDH SGOT SGPT ALP CKNAC ApoA1 ApoB ApoBApoA1 CRP LPa LPO AIP AC CPI CRR significantly ipi  0001 improved hyperlipidemic rat model addition HDLC GSH CAT SOD GPx level elevated Thus current result suggested unpolished CA black rice could effective oxidative stress dyslipidaemia cardiovascular disease due availability numerous functional moiety phenolic compounds",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814438/",
        "source_type": "Global"
    },
    {
        "pmid": "40814364",
        "title": "Transcripts of splicing factors with time-varying associations with survival outcomes in colorectal cancer.",
        "abstract": "Identifying variable timevarying association help guide patient stratification treatment strategies Timevarying association refer association variable interest outcome change time association gene transcript never examined colorectal cancer CRC present study examined transcript splicing factor association prognosis CRC performed analysis using Cox PH model Cox model timevarying coefficient appropriate transcript premRNA processing factor 38A iPRPF38Ai identified significantly associated progressionfree survival two year postdiagnosis that making transcript candidate lateoutcome marker CRC explorative analysis showed transcript correlated alternative splicing gene involved RNA binding mitochondrial protein synthesis Overall study first time revealed association pattern splicing factor transcript time CRC identified transcript iPRPF38Ai candidate lateoutcome marker provided mechanistic insight outcome heterogeneity CRC",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814364/",
        "source_type": "Global"
    },
    {
        "pmid": "40814312",
        "title": "Multiple Model Predictive Control of the Cardiovascular System using Vagal Nerve Stimulation.",
        "abstract": "Vagal nerve stimulation VNS currently investigation treatment various cardiovascular disease include heart failure arrhythmia hypertension preclinical clinical studies VNS stimulation parameter heuristically determined openloop therapeutic efficacy remains inconclusive strongly suggesting need closedloop approach optimize patientspecific stimulation parameters paper develop multiple model predictive control algorithm automated regulation heart rate mean arterial pressure optimally adjusting amplitude frequency electrical pulse applied three location vagal nerve multiple local model identified previously reported pulsatile rat cardiac model emulates symptom hypertension rest exercise states computational expense proposed method verified simulation rigorous hardwareintheloop implementation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814312/",
        "source_type": "Global"
    },
    {
        "pmid": "40814275",
        "title": "Prediction of Sinus Rhythm Maintenance After Electrical Cardioversion Using Spectral and Vector Cardiographic ECG Analysis.",
        "abstract": "Electrical cardioversion ECV remains treatment option atrial fibrillation AF study aimed find predictor SR maintenance ECV using spectral vector cardiographic VCG analysis ECGs Consecutive patient AF referred elective ECV prospectively enrolled digital ECG recording obtained ECV analyzed using spectral VCG analysis AF activity analyzed using spectral analysis determine dominant frequency DF RI regularity index OI organizational index QRS complex analyzed using vectorcardiography determine dXmean dYmean dZmean derivation VCG signals used Lasso Logistic Regression LLR fivefold crossvalidation feature selection build combined predictive model SR maintenance model training evaluation data split 6040 ratio training testing respectively total 80 patient enrolled age 702 ± 106 years 49 61 men BMI 297 kgmsup2sup 3month followup AF recurrence present 36 patient 45 best single VCG parameter predict SR maintenance dZMean OR 018 95 CI 006051 p  0001 VCGdomain parameter combined LLR model showed area curve AUC 078 spectral analysis domain best predictor DF OR 354 95 CI 1281025 p  0006 spectral feature led AUC 076 combined LLR model Clinical feature form model since feature passed feature selection Combining VCG spectral analysis feature led LLR model AUC 079 combination spectral analysis AF activity VCG analysis ventricular activity provided accurate predictive information either analysis alone",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814275/",
        "source_type": "Global"
    },
    {
        "pmid": "40814213",
        "title": "Facilitators, barriers, and insights using an HFA-PEFF-based clinical decision support system: A proof-of-concept study.",
        "abstract": "Knowing heart failure HF preserved ejection fraction HFpEF difficult diagnose clinical decision support system CDSS functional morphological biomarker domains built Therefore research aimed analyse possibility implementing CDSS compliance physician CDSS recommendations well identify obstacle facilitator usage mixedmethods study conducted 1 year period Institute Cardiovascular Diseases Vojvodina Sremska Kamenica Serbia retrospective component included analysis patient symptom andor sign HF ejection fraction EF ≥50 Heart Failure Association pretest assessment echocardiography natriuretic peptide functional testing final aetiology HFAPEFF score used build CDSS calculate probability score patients prospective component involved electronic survey used gain feedback physician CDSS sample included 225 patients 194 862 HFAPEFF score 56 suggesting probable HFpEF syndrome clinically documented discharge report 32 165 patients response rate survey 833 including physician different level education Barriers CDSS usage included lack echocardiographic skill knowledge phenotype profiling HFpEF patients increase explainability transparency well staff education mentioned main facilitators CDSS demonstrated reasonable effectiveness diagnosing classifying patient symptom HF measured EF ≥50 conducted survey highlighted physician education CDSS HFpEFrelated domains key factor battle HFpEF",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814213/",
        "source_type": "Global"
    },
    {
        "pmid": "40814104",
        "title": "Unveiling the UHR threshold in American adult: a new biomarker for early diabetes detection from NHANES study.",
        "abstract": "study examines association serum uric acid highdensity lipoprotein cholesterol ratio UHR biomarker risk prediabetes diabetes relationship remains underresearched provide insight diabetes prevention study utilized data 13975 American participant National Health Nutrition Examination Survey 20112018 Logistic regression models restricted cubic spline RCS analysis subgroup analysis employed examine association UHR prediabetesdiabetes median UHR 104 6382 457 case prediabetes diabetes detected higher UHR associated increased risk prediabetes diabetes showing 39 increased risk per standard deviation increment OR 139 95 CI 133146 Consistent result observed UHR categorized Participants highest UHR quartile exhibited significantly higher risk prediabetesdiabetes lowest quartile OR 263 95 CI 230301 RCS analysis revealed nonlinear association threshold value 1250 threshold higher UHR significantly associated prediabetesdiabetes OR 117 95 CI 115119 threshold association significant Subgroup analysis highlighted marked gender disparity woman exhibiting stronger association research found positive link UHR prediabetes diabetes prevalence nonlinear relationship noted significant association observed UHR threshold 1250 especially females",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814104/",
        "source_type": "Global"
    },
    {
        "pmid": "40814089",
        "title": "Management and safety of same day bilateral intravitreal anti-VEGF injections in a treat-and-extend regimen.",
        "abstract": "Antivascular endothelial growth factor VEGF intravitreal injection treatment IVTs gold standard various neovascular retinal diseases including neovascular agerelated macular degeneration nAMD diabetic macular edema DME macular edema due retinal vein occlusion RVO day bilateral IVTs commonly performed offlabel worldwide reduce patient burden despite limited safety data study evaluates safety management bilateral day antiVEGF injection within treatandextend regimen TER proposes clinical guideline coordination bilateral treatment retrospective observational study analysed electronic health record 428 included patient treated bilaterally ranibizumab 05mg aflibercept 2mg VISTA Augenklinik Binningen Switzerland 2015 2019 Patients included bilateral macular edema due nAMD DME RVO received least two cycle day bilateral antiVEGF injection within TER Treatment coordination followed one four strategies Equal TER Coordinated TER Mixed TER pro nata PRN Asynchronous TER Unilateral IVTs also recorded period patient cohort Ocular systemic adverse event AEs compared unilateral bilateral injection using Fishers exact test total 15825 antiVEGF injection administered 4766 bilateral day injection Formula see text 6293 unilateral injections Treatment interval synchronised according visual acuity potential disease activity treatment regime bilateral IVTs established provided manuscript frequently reported ocular AEs conjunctival haemorrhage sicca symptoms Systemic AEs cerebrovascular cardiovascular event rare significant difference bilateral unilateral injections Bilateral day intravitreal antiVEGF injection within TER regimen appear safe significant increase ocular systemic AEs compared unilateral treatment Coordinating bilateral IVTs using clinical guideline presented study may reduce treatment visits ease patient burden improve compliance Larger prospective study needed confirm safety support standardised guideline bilateral IVTs",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40814089/",
        "source_type": "Global"
    },
    {
        "pmid": "40813723",
        "title": "Sudden cardiac arrest mortality in China: temporal trends and risk factors.",
        "abstract": "Sudden cardiac death SCD account half sudden death cases posing significant health burden China However epidemiological data SCD scarce due lack central data registry heterogeneity case definitions study aim provide reliable estimate incidence risk factor SCD China national regional level 2013 2021 well current status prevention multicause mortality data 2013 2021 obtained National Mortality Surveillance System China Deaths related cardiac arrest identified Crude agestandardized mortality rate calculated time region Joint point regression applied identify significant change study period Subgroup analysis multilevel negative binomial analysis performed understand SCD risk factors firstline prevention measure current implementation China developed country also determined published articles 2013 2021 crude mortality rate sudden cardiac arrest increased markedly 836 death per 100000 population 2013 1859 death per 100000 population 2021 considerable difference among regions Subgroup analysis negative binomial regression result indicated male elderly higher risk SCD SCD may associated poor medical conditions half SCDs occurred outside hospitals approximately 60 SCDs related ischemic heart disease underlying cause Currently developed country widely adopted primary prevention emergency treatment measures however utilization rate measure China relatively low improved continuous rise prevalence cardiovascular disease related risk factor China burden SCD expected increase addition strengthening clinical pathway sudden cardiac arrest case prehospital hospital settings also necessary enhance public awareness knowledge firstline practical training largescale policy governmental communitybased projects",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813723/",
        "source_type": "Global"
    },
    {
        "pmid": "40813585",
        "title": "Collagen VI microfibril structure reveals mechanism for molecular assembly and clustering of inherited pathogenic mutations.",
        "abstract": "Collagen VI link cell surface extracellular matrix provide mechanical strength mammalian tissues linked human disease including muscular dystrophy fibrosis cardiovascular disease osteoarthritis Collagen VI assembles heterotrimers three different αchains microfibrils many gap knowledge molecular assembly process Here determine structure heterotrimeric minicollagen VI construct collagen VI microfibrils mammalian tissue using cryogenicelectron microscopy structure reveal cysteinerich coiled coil region involved trimerisation well microfibril assembly Furthermore structure show pathogenic mutation located interaction site involved different step collagen VI assembly trimericcoiled coil region mediates heterotrimerisation cluster mutation triplehelical region involved microfibril formation microfibril structure provides template understanding supramolecular assembly offer platform rationale design therapeutic collagen VI pathologies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813585/",
        "source_type": "Global"
    },
    {
        "pmid": "40813376",
        "title": "Hypertrophic cardiomyopathy.",
        "abstract": "Hypertrophic cardiomyopathy HCM common inherited cardiomyopathy represents leading cause morbidity mortality HCM sarcomeric disease characterized genetically determined defect sarcomere proteins leading left ventricular hypertrophy hypercontractility diastolic dysfunction phenotypic spectrum disease heterogeneous ranging mild form remain stable asymptomatic many years childhoodonset severe case result progressive heart failure ventricular arrhythmias Multiimaging technique including echocardiography cardiac magnetic resonance pivotal diagnostic prognostic assessment HCM decades therapeutic approach limited invasive septal reduction therapy nonspecific pharmacological treatment heart failure last 10 years however indepth understanding pathological mechanism HCM led development targeted therapies myosin inhibitors proven safe effective improving functional capacity reducing symptoms Innovative therapeutic approaches gene therapy aim target genetic variant underpinning condition currently investigation",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813376/",
        "source_type": "Global"
    },
    {
        "pmid": "40813346",
        "title": "BODIPY-based fluorescent probes distinguish the heterogeneity of lipid droplets in carotid and femoral atherosclerotic plaques.",
        "abstract": "Atherosclerosis AS complex longterm disease major contributor cardiovascular complication leading cause death across globe Lipid droplet LDs closely involved initiation development plaques Therefore visualization quantification complexity LDs may assist understanding biology atherosclerotic plaque assessing lesion stability study report lipophilic fluorescent sensor based BODIPY scaffold iPi1  iPi2 probe exhibited fluorescence responsiveness oilwater system lipid droplet mimic LDMs detection limit low 50 μg mLsup1sup cellular milieu probe effectively tracked LD accumulation induced oxidized lowdensity lipoprotein oxLDL well lipid suppression caused treatment rosiglitazone iEx vivoi imaging atherosclerotic plaque ApoEsupsup mouse human tissue demonstrated probe could distinguish pathological characteristic across various vascular regions Collectively result highlight first application LD sensor sensing distinct lipidic lesion biopsied atherosclerotic plaque patients suggesting organspecific pathogenesis",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813346/",
        "source_type": "Global"
    },
    {
        "pmid": "40813122",
        "title": "Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.",
        "abstract": "provide uptodate evidence key benefits harms uncertainty regarding medication adult type 2 diabetes Living systematic review network metaanalysis NMA using frequentist random effect GRADE grading recommendations assessment development evaluation approaches Updates planned least two time year Medline Embase searched 31 July 2024 current iteration Randomised controlled trial least 24 week comparing one medication standard treatment placebo other systematic review NMA includes 493 168 participant 869 trial adding 53 trial since October 2022 reporting data 13 drug class 63 drugs 26 outcome interest Regarding benefits moderate high certainty evidence confirms well established cardiovascular kidney benefit sodiumglucose cotransporter2 SGLT2 inhibitors glucagonlike peptide1 receptor agonist GLP1RAs finerenone the last patient established chronic kidney disease effective drug reducing body weight tirzepatide mean difference MD 863 kg 95 confidence interval 934 793 moderate certainty orforglipron MD 787 kg 1024 550 low certainty followed eight GLP1RAs high moderate certainty Absolute benefit medication vary substantially depending baseline risk cardiovascular kidney outcomes riskstratified absolute effect medication summarised using interactive multiple comparison tool httpsmatchitmagicevidenceorg250709distdiabetes Regarding medicationspecific harms SGLT2 inhibitor increase genital infection odds ratio OR 329 95 CI 288 377 high certainty ketoacidosis due diabetes OR 208 145 299 high certainty probably increase amputation OR 127 101 161 moderate certainty tirzepatide GLP1RAs probably increase severe gastrointestinal event most increased risk tirzepatide OR 421 187 949 moderate certainty finerenone increase severe hyperkalaemia OR 592 302 1162 high certainty thiazolidinediones increase major osteoporotic fracture probably increase hospitalisation heart failure Sulfonylureas insulin dipeptidyl peptidase4 inhibitor probably increase risk severe hypoglycaemia low low certainty evidence effect diabetesrelated complications including neuropathy visual impairment Despite interest issue uncertainty whether GLP1RAs may reduce dementia OR 092 083 102 low certainty living systematic review provides comprehensive summary cardiovascular kidney weight loss benefits well medicationspecific harm medication adult type 2 diabetes including effect SGLT2 inhibitors GLP1RAs finerenone tirzepatide PROSPERO number CRD42022325948 detailed protocol available httpsdataaliveevidenceorgrecordsq02rvkm486 article first version living systematic review linked living iBMJi Rapid Recommendation living clinical practice guidelines presenting risk stratified recommendation patient type 2 diabetes lower moderate higher risk cardiovascular kidney complications latest evidence made available via iBMJi Rapid Recommendation via interactive GRADE evidence summary MATCHIT httpsmatchitmagicevidenceorg250709distdiabetes Major update published iThe BMJi",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813122/",
        "source_type": "Global"
    },
    {
        "pmid": "40813103",
        "title": "Process for mainstreaming genetic cascade testing into primary and tertiary health systems in familial hypercholesterolaemia (FH), an autosomal dominant, fully penetrant disorder.",
        "abstract": "Advances clinical genomics raised importance integrating genomic medicine across healthcare systems including primary care Primary care present ideal environment offer equitable efficient access genetic services Familial hypercholesterolaemia FH preventable treatable cause premature heart disease represents health condition successfully diagnosed managed primary care study describes process tailoring primarytertiary shared care model FH optimise health professional patient engagement Data collected semistructured interview n10 stakeholder New South Wales Australia Interviews gathered feedback tailor shared care model FH tertiary primary care services Reflexive thematic analysis used analyse interview transcripts Analysis generated three main themes 1 current process genetic testing management 2 challenge genetic testing FH primary care 3 component needed enable tertiaryinitiated shared care model Participants considered model care acceptable could successfully implemented provided key support place assist general practitioners Based results process model integrating genetic testing condition primary care setting developed using FH exemplar process model tailoring primarytertiary model care FH applied across range primary care service treatable genetic conditions",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40813103/",
        "source_type": "Global"
    },
    {
        "pmid": "40812783",
        "title": "Common Predictors of Return To Work across Cardiovascular Diseases.",
        "abstract": "Return work RTW cardiovascular disease CVDs crucial mitigating societal economic burden productivity losses review review explores common diseasespecific predictor RTW within framework International Classification Functioning Disability Health ICF systematic review systematic review conducted identify common diseasespecific predictor RTW individual cardiovascular disease CVDs including acute coronary syndrome ACS chronic coronary artery disease CCAD heart failure HF stroke Predictors analysed across contextual domain personal environmental factors functional domain body structure body function activities participation methodological quality included review evaluated using AMSTAR2 tool total 28 review included Key common predictor included functional capacity psychological wellbeing work characteristic social support diseasespecific predictor involved severity disease treatment characteristics Modifiable factors workplace accommodation psychological challenges identified critical target intervention Early identification atrisk individual integration personalized rehabilitation strategy critical improving RTW outcome healthrelated quality life review enhances understanding RTW predictors contributing optimized rehabilitation process reduced economic burden associated CVDs Future research investigate clinical applicability finding explore broader application common RTW predictor across chronic conditions inform vocational reintegration strategies Word count 238",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40812783/",
        "source_type": "Global"
    },
    {
        "pmid": "40812673",
        "title": "Lysine β-Hydroxybutyrylation in Metabolic Plasticity and Disease Pathogenesis.",
        "abstract": "Lysine βhydroxybutyrylation Kbhb represents novel posttranslational modification PTM mediated ketone body metabolites particularly βhydroxybutyric acid BHB modification exhibit dynamic elevation ketogenic condition including diabetic ketoacidosis neonatal metabolic disorders fasting sustained physical exertion circulating BHB concentration exceed physiological thresholds Emerging evidence position Kbhb critical epigeneticmetabolic interface demonstrated regulatory role spanning oncology immunomodulation cardiovascular homeostasis neuropsychiatric disorders circadian biology developmental processes Mechanistically Kbhb affect metabolic plasticity modulating structural modification key metabolic enzyme well metabolic flux addition Kbhb exerts pleiotropic effect via competitive interplay canonical PTMs acetylation methylation critical lysine residues Kbhbinduced epigenomic reorganization enhancerpromoter domain enrichment facilitates transcriptional activation functional gene mediates transcriptional network progression multiple diseases review systematically examines discovery timeline enzymatic machinery governing Kbhb dynamic writerserasersreaders molecular mechanism underlying pathophysiological functions therapeutic implication across disease states elucidation Kbhbinduced metabolic signaling paradigm molecular interface catalyzes development innovative therapeutic strategy across multiple diseases",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40812673/",
        "source_type": "Global"
    },
    {
        "pmid": "40812670",
        "title": "Telomere-targeted medicine: Bridging molecular mechanisms and clinical applications in age-related diseases.",
        "abstract": "Telomeres nucleoprotein structure end chromosomes emerged critical regulator cellular aging key contributor pathogenesis agerelated diseases comprehensive review examines evolution telomere biology fundamental research therapeutic applications analyzing molecular mechanism telomere dysfunction across diverse disease categories including autoimmune disorders cardiovascular diseases neurodegeneration respiratory diseases metabolic disorders chronic kidney disease cancer premature aging syndromes explore current therapeutic strategy ranging telomerase modulation senolytic approaches highlighting emerging technology drug discovery including CRISPRbased interventions nanomedicine mRNAbased therapies partial cellular reprogramming artificial intelligence applications convergence mechanistic understanding innovative therapeutic approach position telomere biology promising frontier addressing multiple agerelated condition simultaneously potentially shifting medicine reactive disease treatment toward proactive agingfocused prevention However significant challenge remain including safety considerations biomarker development establishing regulatory framework agingtargeted therapeutics success telomeretargeted intervention could herald paradigm shift toward gerosciencebased medicine extending lifespan health span targeting fundamental biological aging processes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40812670/",
        "source_type": "Global"
    },
    {
        "pmid": "40811500",
        "title": "Obstructive Sleep Apnea and Cardiometabolic Disease: Obesity, Hypertension, and Diabetes.",
        "abstract": "Obstructive sleep apnea OSA highly prevalent sleep disorder characterized recurrent upper airway obstruction sleep resulting intermittent hypoxia increased sympathetic activation sleep deficiency past 2 decades robust body evidence support strong link OSA cardiometabolic diseases Obesity important risk factor OSA Observational study indicate OSA strong risk factor development hypertension diabetes Moreover clinical experimental study support causal role OSA hypertension impairment glucose metabolism beyond excess weight Notably OSA particularly underdiagnosed undertreated women may heighten cardiometabolic risk OSA often overlooked pregnancy linked adverse cardiometabolic outcome observational studies randomized clinical trials treatment OSA continuous positive airway pressure reduces blood pressure individual hypertension beneficial effect continuous positive airway pressure glycemic outcome less convincing Inconsistent cardiometabolic response OSA treatment partly explained failure consider heterogeneity OSA variable continuous positive airway pressure adherence among diverse populations review summarize relationship OSA cardiometabolic condition particular focus obesity hypertension diabetes review current knowledge heterogeneity OSA discus potential underlying mechanism impairment blood pressure glucose metabolism OSA also provide clinical perspective OSA management considering current research gap emerging approach prevention treatment cardiometabolic disease",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40811500/",
        "source_type": "Global"
    },
    {
        "pmid": "40811499",
        "title": "Insomnia Phenotypes, Cardiovascular Risk and Their Link to Brain Health.",
        "abstract": "30 40 general population experience insomnia symptom difficulty initiating maintaining sleep another 10 15 general population experience chronic insomnia disorder prevalence insomnia disproportionately higher people cardiometabolic risk factors cardiovascular diseases cerebrovascular diseases neurocognitive disorders including vascular cognitive impairment fact recent metaanalytic evidence epidemiological study demonstrated insomnia especially accompanied objective short sleep duration risk factor incident hypertension type 2 diabetes heart failure stroke cognitive impairment Alzheimer disease allcause mortality Insomnia should thus part prevention management adverse health outcomes However randomized clinical trial demonstrated whether treatment cognitivebehavioral therapy insomnia firstline guidelinerecommended treatment hypnoticssedatives improves heart brainrelated outcomes Studies also failed consider insomnia heterogeneous disorder consisting distinct phenotype result relative contribution biological versus cognitivebehavioral perpetuating factors Objective short sleep duration emerged marker physiological hyperarousal insomnia ie dysregulation hypothalamicpituitary axis increased sympathetic nervous system activation increased inflammation predictor insomniarelated adverse heart brain health outcome and potentially poor response cognitivebehavioral therapy insomnia review summarizes metaanalytic evidence association insomnia cardiometabolic risk factors cardiovascular diseases cerebrovascular diseases neurocognitive disorders including current knowledge heterogeneity disorder review also summarizes potential pathophysiologic mechanism lead heart brain morbidity vary across insomnia phenotype based objective sleep duration review suggests basic clinical science need unveil molecular cellular behavioral mechanism play across insomnia phenotypes public health clinical implication association adverse heart brain health demanding immediate attention",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40811499/",
        "source_type": "Global"
    },
    {
        "pmid": "40811451",
        "title": "Omnipresent intercorrelations of metabolic syndrome markers in the general population.",
        "abstract": "Besides usual characterization metabolic syndrome cluster marker arbitrarily defined thresholds unclear extent marker continuous trait correlated general population present study aimed explore correlation across wide array biological social behavioral characteristics crosssectional analysis performed large populationbased French cohort CONSTANCES 159476 adult blood glucose lowdensity lipoprotein LDL highdensity lipoprotein HDL triglycerides body mass index waist hip circumferences systolic diastolic blood pressure measured time recruitment 2012 2021 Correlations pair continuous marker distribution assessed calculating raw partial correlation coefficient r pattern partial correlation observed little variation group sex age individual parental history cardiovascular disease diagnosis metabolic syndrome social position work environment lifetime unemployment exposure smoking nonmoderate alcohol consumption leisuretime physical inactivity diet quality pattern composed strong expected intercorrelations systolic diastolic blood pressure r ranging 062 074 body mass index waist r 050 063 hip r 058 070 circumference waist hip circumference r 007 019 also includes intercorrelations systolic blood pressure waist r 010 021 hip r 007 012 circumference blood glucose r 009 015 triglyceride blood glucose r 007 016 LDL r 024 033 HDL r 020 029 waist circumference r 007 015 finally waist hip circumference blood glucose r 009 017 008 013 HDL r 012 024 008 018 result show metabolic syndrome marker correlated whatever biological social behavioral characteristic individuals suggest make sense systematically consider marker together rather separately term etiology prevention treatment metabolic disease cardiovascular risk general population",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40811451/",
        "source_type": "Global"
    },
    {
        "pmid": "40810971",
        "title": "WINFOCUS worldwide survey on central venous catheter insertion and position confirmation practices (CVC-ICON study).",
        "abstract": "Central venous catheter CVC essential medicine monitoring drug fluid administration renal replacement therapy Complications arrhythmias endothelial damage thrombosis hemothorax might arise incorrect positioning Despite evidence showing reduction using ultrasound guide insertion correct tip positioning greater accuracy tip position assessment vs chestXray CXR ultrasound adoption greatly varies worldwide study conducted World Interactive Network Focused Critical Ultrasound WINFOCUS aimed assess global practice CVC insertion tip position confirmation webbased survey conducted AprilSeptember 2023 among WINFOCUS membersaffiliates across five continents assessed clinical backgrounds CVC insertion tip position check methods reason using ultrasound Developed WINFOCUS Research subcommittee survey emailed two reminders Data analyzed using SPSS 270 total 1227 respondent 51 response rate participated mainly Europe 335 Asia 283 Americas 309 954 physicians half 513 six year experience placed 200 CVC mostly using ultrasound guidance 70 cases internal jugular vein IJV preferred insertion site 74 Ultrasound used preinsertion assessment 55 vessel puncture 57 less guidewire confirmation 44 CXR remained primary method tip position assessment 52 12 relied solely bedside ultrasound Barriers exclusive ultrasound use included institutional guideline 339 medicolegal concern 138 Despite evidence favoring ultrasound CVC insertion tip position confirmation use remains inconsistent CXR still widely used survey underscore need standardized protocol training enhance US adoption improve patient safety reduce CXR reliance",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810971/",
        "source_type": "Global"
    },
    {
        "pmid": "40810653",
        "title": "Type 2 Diabetes-Associated Phenylacetylglutamine Induces Deleterious Inflammation Cycle in Myeloid Cells through β<sub>2</sub> Adrenergic Receptors and Impedes Wound Healing.",
        "abstract": "Despite advance glucoselowering therapies many diabetic patient still suffer inflammationrelated complication chronic nonhealing wounds microbiotaderived metabolite phenylacetylglutamine PAGln identified causal driver wound via transmissible βsub2subadrenergic receptormediated trainedimmunity loop Metabolomics reveals PAGln elevated type 2 diabetes tightly associated poor healing diabetic nondiabetic human patients Pharmacokinetic comparison show mouse PAGln exposure closely match concentration kinetics seen humans validated PAGln delay wound closure impairs collagen restoration reduces neovascularization wildtype T1DM T2DM micedefects rescued βblocker treatment Mechanistically PAGln epigenetically train myeloid cell via βsub2subadrenergic receptors promoting hyperresponsiveness heightening systemic inflammation epigenetic reprogramming extends HSCs expanding hyperresponsive myeloid cell sustaining myeloidbiased inflammatory loop PAGlninduced hyperinflammatory woundhealing deficit transmissible via bone marrow transplantation irradiated naïve recipients confirming PAGlntrained hematopoietic cell propagate deleterious phenotypes βblockers cotreatment revers PAGlninduced cytokine elevation woundhealing deficits finding link dietderived microbial metabolite PAGln chronic wound inflammation T2DM PAArelated clinical condition highlight βblockade readily translatable therapy disrupt PAGlndriven deleterious inflammation cycle",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810653/",
        "source_type": "Global"
    },
    {
        "pmid": "40810352",
        "title": "From sex hormone decrease to hormonal treatment: impacts on cardiovascular risk with ageing.",
        "abstract": "Ageing play critical role deterioration artery function structure clearly represents first cardiovascular CV risk factor men also women Coronary cerebral artery particularly prone atheroma tissue perfuse particularly vulnerable ischaemia sexes agerelated decrease sex hormone menopause andropause deleterious effect CV health extent hormonal supplementation limit CV risk increased ageing remains controversial Women Health Initiative study main clinical intervention designed evaluate benefitrisk ratio hormone treatment menopause revealed 2002 unexpected increase CV event aged woman 70 years given estrogen plus peculiar synthetic progestin medroxyprogesterone acetate whereas estrogen alone harmful even protective younger woman 60 years pointed double problem progestin now natural progesterone preferred age clinical situation yet clear testosterone CV disease men Related questions analyse summarize i importance dos concentration estrogen testosterone human experimental models allowing define relevantphysiological pharmacological action sex hormone respect medical modulation practice ii main clinical study conducted estrogen androgens term CV protection impact age effects iii mechanism underlying actions iv genderaffirming hormone therapy sex hormone cornerstone gender transition care management",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810352/",
        "source_type": "Global"
    },
    {
        "pmid": "40810347",
        "title": "Camel-Milk-Derived Extracellular Vesicles Mitigate High-Fat-Diet-Induced Obesity by Enhancing Thermogenesis and Modulating Lipid Metabolism in Mice.",
        "abstract": "Obesity significant global health concern linked chronic diseases thermogenic capacity brown adipose tissue BAT crucial obesity treatment study investigates potential camelmilkderived extracellular vesicle mEVs mitigating highfatdietinduced obesity metabolic dysfunction mice result show oral administration mEVs significantly reduces body fat percentage lipid accumulation lowering serum triglycerides free fatty acids cholesterol levels Furthermore mEVs enhance thermogenic capacity cold exposure indicated increased oxygen consumption heat production RNA sequencing BAT reveals mEVs upregulate thermogenesis oxidative phosphorylationrelated genes Additionally mEVs positively modulate gut microbiota promoting beneficial taxon partially restoring shortchain fatty acid production Consequently result suggest mEVs enhance BAT thermogenesis improve metabolic health offering potential therapeutic strategy obesity related disorders",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810347/",
        "source_type": "Global"
    },
    {
        "pmid": "40810307",
        "title": "Artificial Intelligence based fractional flow reserve.",
        "abstract": "Fractional flow reserve FFR  physiological indicator coronary stenosis significance  become widely used parameter also guidance percutaneous coronary intervention PCI Several study shown superiority FFR compared visual assessment contributing reduction clinical endpoints However current approach FFR assessment requires coronary instrumentation dedicated pressure wire thus increasing invasiveness cost duration procedure Alternative noninvasive method FFR assessment based computational fluid dynamic widely tested approach generally fully automated may sometimes require substantial computational power Nowadays one rapidly expanding field medicine use artificial intelligence AI therapy optimization diagnosis treatment risk stratification AI usage contributes development sophisticated method imaging analysis allows derivation clinically important parameter faster accurate way recent years AI utility deriving FFR noninvasive manner increasingly reported review critically summarize current knowledge field AIderived FFR based data computed tomography angiography invasive angiography optical coherence tomography intravascular ultrasound Available solutions possible future direction optimizing cathlab performance including use mixed reality well current limitation standing behind wide adoption techniques overviewed",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810307/",
        "source_type": "Global"
    },
    {
        "pmid": "40810163",
        "title": "Cardioprotective Potential of ApoE-Derived Peptide (ApoEFrag) in Myocardial Infarction in Rats: A Mechanistic Study.",
        "abstract": "Cardiovascular disease CVDs leading cause death among noncommunicable disease globally Myocardial infarction MI one significant CVDs resulting acute chronic myocardial ischemia lead irreversible damage Despite substantial burden posed conditions specific treatment remain limited symptomatic management ApoEFrag shown protective CNS However cardioprotective potential ApoEmimetic investigated Thus study investigates cardioprotective potential ApoEFrag novel ApoEmimetic peptide acute MI model rats MI induced rat two dos isoproterenol 100 mgkg via subcutaneous injection administered 24 h apart ApoEFrag given dos 05 1 mgkg ISOtreated rats Following treatment measured electrocardiogram ECG change arterial ventricular pressure function using PVloop system Plasma heart sample collected biochemical assessments including plasma injury markers hypertrophic index parameters inflammatory markers geneprotein expression analysis histopathological studies ISOinduced MI resulted alteration ECG patterns ventricular dysfunction increased fibrosis elevated hypertrophic index parameters Additionally ISO administration led increased inflammatory marker oxidative stress levels reversed ApoEFrag treatment Furthermore ApoEFrag significantly ameliorated cardiac injury inflammation hypertrophic index parameters ECG alterations ventricular dysfunction cardiac fibrosis ISOinduced MI models Notably ApoEFrag also improved mitochondrial health study suggests ApoEFrag significant cardioprotective potential acute myocardial infarction model",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810163/",
        "source_type": "Global"
    },
    {
        "pmid": "40810152",
        "title": "Exploring Phosphatase and Tensin Homologue Deleted on Chromosome Ten (PTEN) as a Potential Therapeutic Target for Cardiac Hypertrophy.",
        "abstract": "cardiovascular disease continue foremost cause death worldwide heart failure constitutes major segment responsible mortalities Heart failure result exhausted cardiac myocytes lose ability pump blood effectively Cardiac hypertrophy condition heart wherein thickening cardiomyocytes lead abnormal enlargement myocardium PI3KAKTmTOR signaling pathway play pivotal role development cardiac hypertrophy regulating cell growth proliferation metabolism survival cardiac myocytes phosphatase tensin homologue deleted chromosome ten PTEN membranebound lipid phosphatase facilitates dephosphorylation PIP3 PIP2 thus preventing hyperactivation PI3KAKTmTOR signaling pathway Augmentation PTEN expression activity hinder cardiac hypertrophy mitigate risk heart failure present review discusses role PTEN controlling unchecked cardiomyocyte proliferation provides account novel finding current research noncoding RNAs protein interacting PTEN review discusses pharmacological agent restore PTEN expression function may emerge effective therapeutic treatment cardiac hypertrophy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810152/",
        "source_type": "Global"
    },
    {
        "pmid": "40810106",
        "title": "Attributable burden of steatotic liver disease on cardiovascular outcomes in Asia.",
        "abstract": "association metabolic dysfunctionassociated steatotic liver disease MASLD specific cardiovascular events well attributable burdens remain inconsistent underexplored within single population largescale prospective cohort evaluated association MASLD various cardiovascular outcomes Two additional steatotic liver disease SLD subtypes  MASLD increased alcohol consumption MetALD alcoholrelated liver disease ALD  also evaluated included 303589 adult aged ≥30 year Taiwan underwent health examination 1997 2013 MASLD defined ultrasounddetected steatosis limited alcohol intake ≥1 cardiometabolic risk factor MetALD ALD defined based alcohol intake threshold cardiometabolic profiles Participants followed 2020 outcome mortality ascertained via linkage national registries Cox proportional hazard model used estimate adjusted relative risk RRs population attributable fraction PAFs calculated total population 91877 303 MASLD 7490 25 MetALD 5576 18 ALD 198646 654 SLD median followup 104 years 162959 cardiovascular event occurred adjusted RR cardiovascular disease 129 95 CI 138131 MASLD 138 95 CI 134142 MetALD 148 95 CI 143153 ALD Among SLD subtypes MASLD showed highest RR myocardial infarction RR 146 95 CI 136156 Findings remained consistent accounting liverrelated deaths PAF MASLD 807 95 CI 781858 Despite higher risks MetALD ALD lower PAFs due lower prevalence major SLD subtypes  MASLD MetALD ALD  associated increased longterm cardiovascular risk underscoring need early detection cardiometabolic risk management across SLD spectrum largescale study 303589 individual demonstrates metabolic dysfunctionassociated steatotic liver disease MASLD increase risk cardiovascular disease least 29 Cardiovascular risk escalates across SLD subtypes higher level alcohol consumption Notably MASLD associated highest risk myocardial infarction among SLD subtypes quantifying population burden found 807 cardiovascular event may preventable effective MASLD prevention strategies highlighting critical role cardiometabolic risk management finding emphasize need integrate MASLD identification prevention broader cardiometabolic care public health frameworks applicable",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40810106/",
        "source_type": "Global"
    },
    {
        "pmid": "40809958",
        "title": "Emerging roles of tsRNAs in programmed cell death and disease therapeutics: challenges, opportunities, and future directions.",
        "abstract": "Programmed cell death PCD includes various form apoptosis autophagy necroptosis pyroptosis ferroptosis play pivotal role disease pathogenesis progression tRNAderived small RNAs tsRNAs emerged crucial regulator processes influencing cellular fate disease outcomes Research revealed diverse expression profile tsRNAs across various diseases emphasizing role modulating PCD pathway potential value diagnosis treatment Specific tsRNAs either promote inhibit apoptosis example tsRNA3043a promotes ovarian granulosa cell apoptosis premature ovarian insufficiency whereas tsRNA04002 prevents apoptosis nucleus pulposus cell delay intervertebral disc degeneration Furthermore tsRNAs serve potential biomarkers early disease detection emerging detection technology enhancing clinical utility Therapeutically tsRNAtargeted strategies RNA interference exosomebased drug delivery offer new avenue modulating PCD disease cancer cardiovascular disorders neurodegenerative diseases Despite challenge understanding tsRNA biogenesis functional diversity role regulating PCD highlight strong potential advancing disease diagnostics treatment strategies personalized medicine",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40809958/",
        "source_type": "Global"
    },
    {
        "pmid": "40809950",
        "title": "Concurrent Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patient Treated With Daratumumab and Tafamidis: A Case Report.",
        "abstract": "Immunoglobulin light chain AL wildtype transthyretin ATTRwt amyloidosis sharing similar clinical presentations require distinct treatments report rare case 75yearold man heart failure diagnosed concurrent AL ATTRwt cardiac amyloidosis Immunohistochemistry liquid chromatographytandem mass spectrometry confirmed AL ATTR amyloid deposit heart patient safely effectively treated daratumumabbased chemotherapy followed tafamidis case underscore necessity precise amyloid typing tailored therapy suggesting sequential daratumumab tafamidis viable strategy complex overlap bTrial Registrationb author confirmed clinical trial registration needed submission",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40809950/",
        "source_type": "Global"
    },
    {
        "pmid": "40809732",
        "title": "Clinical Significance of Serum Total Testosterone Concentration in Japanese Elderly Women With Pre-Heart Failure With Preserved Ejection Fraction.",
        "abstract": "Currently limited information available regarding testosterone woman heart failure preserved ejection fraction HFpEF crosssectional study aimed elucidate clinical significance serum total testosterone concentration TT Japanese elderly woman preHFpEF condition develops onset HF total 232 elderly woman outpatient preHFpEF mean age ± standard deviation 75 ± 7 years enrolled Relationships TT clinical parameter investigated definition preHFpEF study patient left ventricular ejection fraction 50 Ee ratio marker left ventricular function greater 9 echocardiography HF symptom history HF hospitalization significantly negative correlation TT Ee ratio r  024 P  0001 low TT significantly related coronary artery disease significant correlation observed TT biomarkers blood brain natriuretic peptide concentration r  031 P  0001 serum highsensitivity cardiac troponin concentration r  033 P  0001 derivativesreactive oxygen metabolite test oxidative stress marker r  046 P  0001 Furthermore multiple regression analysis identified factor described selected independent variable TT dependent variable crosssectional study indicated low TT level reflect unfavorable pathophysiological condition Japanese elderly woman preHFpEF clarify relevance TT predictive indicator onset cardiovascular diseases including HF incidence elderly woman preHFpEF future prospective studies including interventional treatments conducted",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40809732/",
        "source_type": "Global"
    },
    {
        "pmid": "40809699",
        "title": "A Common Genetic Background for Psoriasis and Cardiovascular Diseases: A Narrative Review.",
        "abstract": "Psoriasis immunemediated disease affecting primarily skin joints also systemic implications assumption common genetic background psoriasis cardiovascular diseases narrative review aim provide overview existing data regarding IL23 rs2066808 IL23R rs2201841 IL17RA rs4819554 IL17A rs2275913 polymorphism link psoriasis cardiovascular diseases PubMed Web Science Scopus SNPedia search conducted identify relevant study 2007 2025 investigated association psoriasis cardiovascular diseases IL23 rs2066808 IL23R rs2201841 IL17RA rs4819554 IL17A rs2275913 polymorphisms existing data conflicting polymorphism could implicated psoriasis onset disease susceptibility treatment response also linked coronary artery disease Contradictory data could result heterogeneity population included study laboratory technique used polymorphism determination interplay IL17 IL23 genetic polymorphism illustrates complex landscape psoriasis associated comorbidities standardized casecontrol study needed confirm hypothesis Moreover extensive study diverse population would important clarify relationship potential implication treatment management",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40809699/",
        "source_type": "Global"
    },
    {
        "pmid": "40809444",
        "title": "Predictors of uveitic macular edema and functional prognostic outcomes: real-life data from the international AIDA Network uveitis registry.",
        "abstract": "detect factor capable predicting development macular edema ME throughout disease course patient affected noninfectious uveitis NIU Predictive factor leading development analyzed regression analysis functional impact best corrected visual acuity BCVA also examined total 1160 NIU patient 1857 eyes analyzed observed 148 1276 affecting 211 eyes significantly frequent patient nonanterior NIU ipi  00001 RR  401 retinal vasculitis ipi  00001 structural complication ipi  00005 Gender HLAB27 andor HLAB51 positivity ethnicity show significant impact prevalence ipi  0635 ipi  0372 ipi  0193 respectively Four variable associated development NIU course nonanterior anatomical pattern ipi  00001  401 presence retinal vasculitis ipi  0028  168 complication ipi  0044  151 immunosuppressive treatment ipi  0010 169 diagnosis Behçet diseaserelated uveitis less likely associated development ipi  024 0545 Mean ± SD BCVA significantly lower eye 082 ± 030 compared eye without 071 ± 033 develop across NIU types likely case involving posterior segment retinal vasculitis Regular focused monitoring recommended highrisk patients study also highlight limited predictive value demographic HLArelated factors helping refine clinical risk stratification predictive modeling NIU",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40809444/",
        "source_type": "Global"
    },
    {
        "pmid": "40809152",
        "title": "Prevalence and Pathogenetic Mechanisms of Chronic Kidney Disease in Autoimmune-Mediated Systemic Diseases.",
        "abstract": "Chronic kidney disease CKD affect estimated 15 adult Central Europe affected high risk cardiovascular disease death Inflammatory rheumatic systemic disease manifest extraarticularly varying frequency article summarized prevalence pathogenetic mechanism CKD rheumatic systemic diseases following database searched references PubMed Web Science Cochrane Library Scopus search period spanned 1975 2025 Kidney involvement almost always present systemic lupus erythematosus certain type systemic vasculitis context rheumatic diseases additional mechanism contribute enhancing functional structural integrity kidneys mechanism include inflammation increase cardiovascular risk prevalence CKD disproportionately high certain entity rheumatic form Given disproportionately high prevalence CKD relevant entity inflammatory rheumatic group associated increase risk cardiovascular disease death CKD screening integral part care affected patients",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40809152/",
        "source_type": "Global"
    },
    {
        "pmid": "40808951",
        "title": "Transcriptional responses in different mouse models of septic liver injury differ from those in patients with septic liver injury.",
        "abstract": "Sepsis particularly sepsisinduced liver injury SLI exhibit acute onset high mortality up 80 murine model widely used mechanistic study due limited human sample availability accuracy replicating human SLI pathophysiology remains debated Human SLI transcriptomes characterized identify core gene immune signature using Venn analysis immune infiltration profiling Transcriptomic feature two murine SLI modelscecal ligation puncture CLP lipopolysaccharide LPS challengewere benchmarked human SLI evaluate pathophysiological relevance model utilized validate core gene expression SLI biomarker identification Human SLI transcriptomics revealed significant enrichment apoptotic processes NFκB regulation inflammatory responses protein phosphorylation bacterial response Key pathway included IL17 signaling antigen processing estrogen signaling atherosclerosis Immune infiltration confirmed multifactorial immune cell involvement murine model recapitulated inflammatory immune responses LPS model mimicking human SLI via chemotaxis phagocytosis NODlike receptor signaling leukocyte migration CLP model uniquely replicated neutrophil chemotaxis apoptosis ER stress IL17 TNF signaling SOCS3 validated potential SLI biomarker Murine model partially replicate human SLI pathology exhibit distinct mechanistic emphases Careful model selection essential biomarker discovery eg SOCS3 pathogenic mechanism exploration highlighting inherent model limitations",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40808951/",
        "source_type": "Global"
    },
    {
        "pmid": "40808542",
        "title": "Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF.",
        "abstract": "Guidelinerecommended medical therapy GRMT improves outcome heart failure HF reduced ejection fraction HFrEF yet implementation remains suboptimal TITRATEHF prospectively evaluated GRMT implementation across different HFrEF stages effect 1year prognosis left ventricular ejection fraction LVEF TITRATEHF observational cohort study across 48 hospital Netherlands June 2022February 2024 total 4288 patient enrolled primary analysis includes 12month followup data HFrEF patient n  3367 stratified de novo chronic worsening HF Longitudinal trend GRMT prescription rate dosage analysed Serial echocardiographic data assessed change LVEF baseline 12 months KaplanMeier analysis assessed composite endpoint allcause death HF hospitalization Median age 71 year interquartile range IQR 6378 29 female 56 nonischaemic cardiomyopathy de novo HFrEF n  1353 quadruple therapy 472 6 weeks 647 3 months 695 6 months 644 12 months chronicworsening HFrEF n  1625 quadruple therapy increased 446 baseline 546 12 months primarily driven greater sodiumglucose cotransporter 2 inhibitor uptake 660 785 Among de novo HFrEF patient serial echocardiogram n  752 median LVEF improved 10 IQR 317 ischaemic versus 15 IQR 924 nonischaemic cardiomyopathy p  0001 Early quadruple GRMT initiation within 6 weeks higher 6month dos associated greater LVEF improvement 12 months composite endpoint occurred 133 133 438 de novo chronic worsening HFrEF patients respectively finding highlight importance early intensive GRMT implementation emphasize need continuous dose titration beyond initial phase improve LVEF clinical outcomes",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40808542/",
        "source_type": "Global"
    },
    {
        "pmid": "40807750",
        "title": "Advancements in Sensor Technology for Monitoring and Management of Chronic Coronary Syndrome.",
        "abstract": "Chronic Coronary Syndrome CCS significantly impact quality life increase risk adverse cardiovascular events remaining leading cause mortality worldwide use sensor technology medicine emerging promising approach enhance management monitoring patient across wide range diseases Recent advancement engineering nanotechnology enabled development ultrasmall device capable collecting data critical physiological parameters Several sensor integrated wearable implantable devices instrument exhaled gas analysis smart stent tool capable real time biochemical analysis developed demonstrated effective CCS management application CCS could provide valuable insight disease progression ischemic events patient response therapy Moreover sensor technology support personalization treatment plans enable early detection disease exacerbations facilitate prompt interventions potentially reducing need frequent hospital visit unnecessary invasive diagnostic procedure coronary angiography review explores sensor integration CCS care highlighting technological advances clinical potential implementation challenges",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40807750/",
        "source_type": "Global"
    },
    {
        "pmid": "40807193",
        "title": "Obstructive Sleep Apnea and Type 2 Diabetes: An Update.",
        "abstract": "Obstructive sleep apnea OSA syndrome severe debilitating pervasive sleep disorder OSA mainly affect people obesity type 2 diabetes mellitus T2DM hypertension dyslipidemia strongly associated cardiovascular complications Based bidirectional relationship T2DM OSA latter represents risk factor former and vice versa people T2DM high risk OSA Mechanical hormonal factors inflammatory mediators dysregulated autonomic nervous system contribute mechanism underlying disease Treatment OSA necessary even available remedy always effective addition traditional treatments including lifestyle adaptation bariatric surgery CPAP equipment ie breathing device ensuring continuous positive pressure keep airway open sleep represents common treatment tool recently pharmacological research paved way newer seemingly effective therapeutic strategy involving particular two hypoglycemic agent classes ie sodiumglucose cotransporter 2 inhibitor SGLT2is glucagonlike peptide1 GLP1 receptor agonist GLP1ras narrative review provides update above",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40807193/",
        "source_type": "Global"
    },
    {
        "pmid": "40807063",
        "title": "The Role of Obstructive Sleep Apnea in Pulmonary Hypertension Associated with Lung Diseases (Group 3 Pulmonary Hypertension): A Narrative Review.",
        "abstract": "Obstructive sleep apnea OSA could increase pulmonary artery pressure However clinical consequence vary mainly depending comorbidities Patients pulmonary hypertension associated lung disease World Health Organization WHO Group 3 pulmonary hypertension particularly vulnerable increase pulmonary artery pressure Managing pulmonary hypertension specific patient population present considerable challenge positive airway pressure therapy OSA shown promise improving pulmonary hemodynamics patient obesity hypoventilation syndrome chronic obstructive pulmonary disease evidence lacking similar improvement pulmonary disease hypoventilation disorders Furthermore pulmonaryarteryspecific therapy may carry risk clinical worsening group Weight management new pharmacotherapy together emerged crucial intervention demonstrating benefit OSA pulmonary hemodynamics reviewed key study provide insight influence OSA Group 3 pulmonary hypertension clinical management conditions",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40807063/",
        "source_type": "Global"
    },
    {
        "pmid": "40807057",
        "title": "A Critical Appraisal of Off-Label Use and Repurposing of Statins for Non-Cardiovascular Indications: A Systematic Mini-Update and Regulatory Analysis.",
        "abstract": "bBackgroundb Statins exhibit pleiotropic antiinflammatory antioxidant immunomodulatory effects suggesting potential noncardiovascular conditions However evidence supporting repurposing remains limited offlabel prescribing policy vary globally bObjectiveb systematically review evidence statin repurposing oncology infectious diseases assess Hungarian regulatory practice regarding offlabel statin use bMethodsb systematic literature search PubMed Web Science Scopus ScienceDirect 2010May 2025 conducted using term drug repositioning offlabel prescription statin cardiovascular following PRISMA guidelines Hungarian offlabel usage data NNGYK 20082025 also analyzed bResultsb 205 publications 12 met inclusion criteria75 oncologyfocused 25 focused infectious diseases preclinical 58 25 offered strong clinical evidence Applications included hematologic malignancies solid tumors Cryptococcus neoformans SARSCoV2 dengue virus Mechanisms involved mevalonate pathway inhibition modulation host immune responses Hungarian data revealed five approved offlabel statin usesthree dermatologic two pediatric metabolicsupported literature requiring posttreatment reporting bConclusionsb preclinical finding promising clinical validation offlabel statin use remains limited Statins continued cancer patient cardiovascular indications initiation purpose trialbased Future direction include biomarkerbased personalization regulatory harmonization costeffectiveness studies",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40807057/",
        "source_type": "Global"
    },
    {
        "pmid": "40806978",
        "title": "Non-Invasive Positive Pressure Ventilation for Pre-Oxygenation of Critically Ill Patients Before Intubation.",
        "abstract": "Preoxygenation key step prior endotracheal intubation particularly critically ill patient prevent lifethreatening periprocedural hypoxemia narrative review explores emerging interest NonInvasive Positive Pressure Ventilation NIPPV preoxygenation modality intensive care unit ICU context reviewed data randomized controlled trial RCTs observational study published 2000 2024 compare NIPPV conventional oxygen therapy High Flow Nasal Cannula Oxygen HFNCO pathophysiological mechanism successful use NIPPV including alveolar recruitment decrease shunting maintenance functional residual capacity reviewed depth Existing study show NIPPV significantly prolongs apnea time reduces rate periintubation severe hypoxaemia selected patient especially effective patient acute hypoxaemic respiratory failure Nevertheless appropriate patient selection still crucial disease contraindicate even harmful NIPPV discussed practical aspect use ventilatory support the best ventilator settings interface apply it lastly discus unanswered question offer suggestion opportunity future exploration guiding role NIPPV use preoxygenation critically ill patient requiring emergent airway management",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806978/",
        "source_type": "Global"
    },
    {
        "pmid": "40806975",
        "title": "A Comprehensive Review of a Mechanism-Based Ventricular Electrical Storm Management.",
        "abstract": "electrical ventricular storm VES defined multiple sustained ventricular arrhythmia arising short time often refractory standard antiarrhythmic treatment three pillar physiopathogenesis VES autonomic dysfunction triggers altered ventricular substrate Incessant highly recurrent ventricular arrhythmia impact hemodynamic status worsening heart failure increasing mortality stepwise teambased tailored therapeutic approach required stop ventricular arrhythmia regain hemodynamic electric stability patient author focused describing currently available therapeutic approach VES intending establish best VES therapeutic approaches process involves considering patients specific condition response previous treatments potential risk benefit approach option range adjusting antiarrhythmic therapy reprogramming ICD sedation epidural anaesthesia stellate ganglion anaesthetic block use ECMO left ventricular assist device radiofrequency catheter ablation Particular attention paid detailed management genetic primary arrhythmia syndrome like longQT syndrome catecholaminergic polymorphic ventricular tachycardia Brugada syndrome WolffParkinsonWhite syndrome early repolarisation syndrome right ventricular arrhythmogenic dysplasia idiopathic ventricular fibrillation overcoming acute event VES obtaining hemodynamic stability treatment shift toward optimal balance heart failure therapy controlling substrate revascularisation procedure resolving pathologygenerating ventricular arrhythmias article provides comprehensive overview ESVs current management option using efficient strategy known date",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806975/",
        "source_type": "Global"
    },
    {
        "pmid": "40806960",
        "title": "Topical Chlormethine Gel in the Treatment of Lymphomatoid Papulosis: A Case Report and Literature Review.",
        "abstract": "bBackgroundb Lymphomatoid papulosis LyP primary cutaneous CD30positive Tcell lymphoproliferative disorder presenting selfhealing erythematous papulonodular lesion may ulcerate scar Treatment varies lesion extent location severity bCase Reportb describe 57yearold man acral LyP successfully treated chlormethine gel CG patient experienced impaired second finger mobility 3 month due ulcerated nodular mass 3 month CG treatment complete remission symptom resolution full joint recovery achieved Six month posttreatment patient remained remission bConclusionsb case underscore effectiveness CG achieving sustained remission acral LyP suggesting potential treatment option rare condition",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806960/",
        "source_type": "Global"
    },
    {
        "pmid": "40806809",
        "title": "Fentanyl Research: Key to Fighting the Opioid Crisis.",
        "abstract": "bBackgroundObjectiveb Fentanyl play pivotal role opioid epidemic defined four wave overdose deaths analyse fentanyl research trends examining link mental health pharmaceutical development healthcare diseases pathophysiology within broader social health context time bMethodsb understand evolution scientific publication fentanyl relationship opioid crisis search using Web Science Core Collection PubMed conducted total 53670 document retrieved related opioid scientific production among 1423 article 3 focused specifically fentanyl 21546 MeSH term identified document analysed publication year specific fields Psychiatry Psychology Chemicals Drugs Healthcare Diseases Phenomena Processes RstatisticalFactoMineR library used correspondence analysis bResultsb first overdose death wave research focused improving therapy reducing side effects second wave emphasised detoxification method naltrexone methadone behavioural therapies third wave addressed psychological treatment HIVsyringesharing prevention fourth wave prioritised less addictive analogue understanding consumer profile combat epidemic bConclusionsb Fentanyl research evolved alongside realworld challenges reinforcing connection patients needs healthcare professionals roles illicit users policymakers research communitys contribution addressing therapeutic use broader societal impact finding highlight necessity interdisciplinary approach scientific research integrating prevention treatment education legal reform social support emphasising need public health policy collaborative research mitigate impact",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806809/",
        "source_type": "Global"
    },
    {
        "pmid": "40806717",
        "title": "Revitalizing Colchicine: Novel Delivery Platforms and Derivatives to Expand Its Therapeutic Potential.",
        "abstract": "Colchicine potent alkaloid wellestablished antiinflammatory properties show significant promise treating classic immunemediated inflammatory diseases well associated cardiovascular diseases including atherosclerosis However clinical use limited narrow therapeutic window doselimiting systemic toxicity variable bioavailability clinically significant drugdrug interactions partly mediated modulation Pglycoprotein cytochrome P450 3A4 metabolism review explores advanced delivery strategy designed overcome limitations critically evaluate lipidbased systems solid lipid nanoparticles liposomes transferosomes ethosomes cubosomes polymerbased nanoparticles microneedles implants including drugeluting stents system ensure targeted delivery improve pharmacokinetics reduce toxicity Additionally discus chemical derivatization approaches prodrugs codrugs strategic ring modification A B Crings aimed optimizing efficacy safety profile colchicine Combinatorial nanoformulations enable codelivery colchicine synergistic agents glucocorticoid statins well theranostic platform integrate therapeutic diagnostic functions also considered innovative delivery system derivative potential transform colchicine therapy broadening clinical application minimizing adverse effects Future challenge include scalable manufacturing longterm safety validation translation research clinical practice",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806717/",
        "source_type": "Global"
    },
    {
        "pmid": "40806606",
        "title": "Role of Dyadic Proteins in Proper Heart Function and Disease.",
        "abstract": "Cardiovascular disease encompasses wide group condition affect heart blood vessels diseases cardiomyopathy arrhythmia specifically wellstudied relationship cardiac dyads nanoscopic structure connect electrical signal muscle contraction proper development positioning dyad essential excitationcontraction EC coupling and thus beating heart Three proteins namely CMYA5 JPH2 BIN1 responsible maintaining dyadic cleft Ttubule junctional sarcoplasmic reticulum jSR Various dyadic protein play integral role primary function dyadtranslating propagating action potential AP myocardial contraction Casup2sup secondary messenger process act allosteric activator sarcomere cytoplasmic concentration regulated dyad Lossoffunction mutation shown result cardiomyopathy arrhythmias Adenoassociated virus AAV gene therapy dyad component rescue dyadic dysfunction result cardiomyopathy arrhythmias Overall dyad component serve essential mediator calcium homeostasis excitationcontraction coupling mammalian heart and dysfunctional result significant cardiac dysfunction arrhythmias morbidity mortality",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806606/",
        "source_type": "Global"
    },
    {
        "pmid": "40806443",
        "title": "The Role of Advanced Glycation End-Products in the Pathophysiology and Pharmacotherapy of Cardiovascular Disease.",
        "abstract": "Advanced glycation endproducts AGEs formed nonenzymatic glycation proteins lipids nucleic acid due consumption highcarbohydrate diets production also promoted sedentary lifestyle well cigarette smoking Elevated level AGEs circulatory system internal organ body commonly observed number cardiovascular disease hypertension diabetes atherosclerosis coronary artery disease aortic aneurysm atrial fibrillation myocardial infarction heart failure associated development oxidative stress myocardial inflammation adverse effect AGEs cardiovascular system elicited nonreceptor mechanism involving crosslinking extracellular intracellular proteins receptormediated mechanism involving binding AGEs advanced glycation endproduct receptor RAGEs cell membrane AGERAGE interaction along crosslinking protein promote generation oxidative stress production inflammation occurrence intracellular Casup2supoverload alteration extracellular matrix leading development cardiovascular dysfunction AGEs also bind two protein receptor circulatory system soluble RAGEs sRAGEs released upon proteolysis RAGEs due activation matrix metalloproteinase endogenous secretory RAGEs esRAGEs secreted spliced variant endogenous RAGEs AGERAGE signal transduction axis serf pathogenic mechanism sRAGEs esRAGEs serve cytoprotective interventions serum level sRAGEs decreased ischemic heart disease vascular disease heart failure well cardiovascular diseases increased chronic diabetes renal disease Several intervention reduce formation AGEs block AGERAGE axis increase level circulating sRAGEs shown exert beneficial effect diverse cardiovascular diseases observation support view AGERAGE axis play critical role pathogenesis also excellent target treatment cardiovascular disease",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806443/",
        "source_type": "Global"
    },
    {
        "pmid": "40806350",
        "title": "Cardioprotective Role of Captopril: From Basic to Applied Investigations.",
        "abstract": "Captopril wellestablished angiotensinconverting enzyme ACE inhibitor garnered attention cardioprotective effect preventing heart remodeling maintaining cardiac function significantly improving life quality However recent study revealed addition known hemodynamic alterations captopril exhibit significant antioxidant antiinflammatory immunomodulatory effect may underlie protective mechanisms Although appeared overlooked clinical practice recent years additional effort made uncover mechanism drug effects recent research study predict wide spectrum disease beyond recommended indications review thoroughly examines mechanism captopril mediates protective effects bridging basic biochemical observation applied clinical investigation especially ischemic reperfusion IR injury hypertension heart failure HF Evidence point captopril promising agent modulating oxidative inflammatory pathway crucial cardiovascular medicine Directions future research defined determine molecular target captopril optimize clinical utility management cardiovascular possibly diseases",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806350/",
        "source_type": "Global"
    },
    {
        "pmid": "40806149",
        "title": "Long-Term Outcomes of the Dietary Approaches to Stop Hypertension (DASH) Intervention in Nonobstructive Coronary Artery Disease: Follow-Up of the DISCO-CT Study.",
        "abstract": "original randomised Dietary Intervention Stop Coronary Atherosclerosis DISCOCT trial 12month Dietary Approaches Stop Hypertension DASH project led dietitian improved cardiovascular metabolic risk factor reduced platelet chemokine level patient coronary artery disease CAD unclear whether benefit sustained determine whether metabolic inflammatory clinical benefit achieved DISCOCT trial sustained six year structured intervention ended Ninetyseven adult nonobstructive CAD confirmed coronary computed tomography angiography randomly assigned receive optimal medical therapy control group ini  41 therapy combined intensive DASH counselling DASH group ini  43 301 ± 22 weeks 84 individual 87 given consent underwent reassessment body composition meal frequency assessment biochemical testing lipids hsCRP CXCL4 RANTES homocysteine Major adverse cardiovascular event MACE assessed intervention DASH group lost average 36 ± 42 kg reduced total body fat average 42 ± 48 kg compared average loss 11 ± 29 kg reduction total body fat 03 ± 41 kg control group both ipi  001 Six year later lost body weight fat tissue regained sharp increase visceral fat area group ipi  00001 CXCL4 decreased 43 ± 30 ngmL intervention remained lower baseline values contrast control group initially increased decreased ipi  0001 groups LDL cholesterol hsCRP level returned baseline group remained baseline DASH group one case MACE DASH group compared four case including one fatal myocardial infarction control group ipi  0575 Overall adherence DASH project increased 26 point counselling decreased four points remaining higher control group oneyear DASH project supported physician dietitian resulted longterm suppression proatherogenic chemokine CXCL4 fewer MACE six years despite decline adherence loss anthropometric lipid benefits appears sustained systemic reinforcement behaviour necessary maintain benefit lifestyle intervention CAD",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806149/",
        "source_type": "Global"
    },
    {
        "pmid": "40806137",
        "title": "Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich <i>n</i>-3 PUFA Supplementation.",
        "abstract": "Menopause increase risk cardiovascular disease CVD accompanied decline muscle function Myokines released skeletal muscle could play significant role cardiovascular health study aimed investigate change induced 16week resistance training RT program andor docosahexaenoic acid DHArich ini3 PUFA supplementation myokine cytokine circulating level study association parameter body composition muscle function glucose lipid serum marker postmenopausal woman overweightobesity baseline interleukin6 IL6 level positively correlated body fat tumor necrosis factoralpha TNFα level negatively associated meterorinlike METRNL levels Moreover METRNL inversely associated insulin level HOMAIR intervention muscle quality improved either treatment notably response RT iNi3 supplementation caused significant improvement cardiometabolic health markers TNFα decreased experimental groups Myostatin level decreased RT ini3 groups IL6 increased ini3RT group Lastly interaction treatment observed postmenopausal woman overweight obesity RT could help improve skeletal muscle function DHArich ini3 supplementation might decrease CVD risk might potentially improve muscle function modulation myokine level could underlying effect DHA RT however research necessary",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806137/",
        "source_type": "Global"
    },
    {
        "pmid": "40806117",
        "title": "Influence of Matcha and Tea Catechins on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-A Review of Patient Trials and Animal Studies.",
        "abstract": "Metabolic dysfunctionassociated fatty liver disease MASLD chronic noncommunicable spectrum disease characterized lipid accumulation often asymptomatic prevalence varies region age gender economic status estimated 25 worlds population currently suffer MAFLD 20 million patient die MAFLDrelated diseases last 20 years tea antiobesity research indicated regularly consuming tea decrease risk cardiovascular disease stroke obesity diabetes metabolic syndrome MeS review aimed present study concerning influence matcha extract epigallocatechin3 gallate EGCG supplement metabolic function context MAFLD human animal studies published data show promise human animal studies beneficial effect body weight cholesterol levels liver metabolism function noted even shortperiod experiments safety level EGCG green tea extract consumption marked experiment needed confirm result observed animal study show mechanism green tea exerts effects preliminary data research concerning microbiota epigenetic change observed polyphenols green tea consumption need expanded improve efficiency availability green tea supplement consumption treatment MAFLD patients research larger group longer study duration needed",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806117/",
        "source_type": "Global"
    },
    {
        "pmid": "40806086",
        "title": "Gut-Microbiota-Derived Metabolites and Probiotic Strategies in Colorectal Cancer: Implications for Disease Modulation and Precision Therapy.",
        "abstract": "human gut microbiota significantly influence host health metabolic product interaction immune neural metabolic systems Among these shortchain fatty acid SCFAs especially butyrate play key role maintaining gut barrier integrity modulating inflammation supporting metabolic regulation Dysbiosis increasingly linked diverse condition gastrointestinal metabolic neuropsychiatric disorders cardiovascular diseases colorectal cancer CRC Probiotics offer therapeutic potential restoring microbial balance enhancing epithelial defenses modulating immune responses review highlight physiological function gut microbiota SCFAs particular focus butyrates antiinflammatory anticancer effect CRC also examines emerging microbial therapy like probiotics synbiotics postbiotics engineered microbes Emphasis placed need precision microbiome medicine tailored individual hostmicrobiome interaction metabolomic profiles insight underscore promising role gut microbiota modulation advancing preventive personalized healthcare",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40806086/",
        "source_type": "Global"
    },
    {
        "pmid": "40805894",
        "title": "Neurocognitive and Psychosocial Interactions in Atrial Fibrillation: Toward a Holistic Model of Care.",
        "abstract": "bBackgroundObjectivesb Psychosocial PS factor cognitive dysfunction CD patient atrial fibrillation AF may negatively impact treatment compliance PS profile cover multiple psychological socioeconomic factors although research mostly limited depression anxiety work stress study assessed prevalence broad range PS factor patient AF relationship cognitive decline bMethodsb retrospectively analyzed data patient referred cardiovascular rehabilitation clinic March 2017 April 2023 underwent standardized assessment PS factors cognition quality life bResultsb 798 included patients 230 288 AF mean age 6807 year SD 960 years Six nine PS factor present half overall sample Compared nonAF patients AF showed significantly higher level social isolation depression hostility whereas low socioeconomic status family workrelated stress mental disorder frequent nonAF group CD present 674 total cohort prevalent AF patient higher PS burden Patients permanent AF reported poorest health status bConclusionsb Integrating assessment PS factor cognition cardiac rehabilitation feasible support comprehensive patientcentred model care AF",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40805894/",
        "source_type": "Global"
    },
    {
        "pmid": "40805864",
        "title": "Effectiveness of Acceptance and Commitment Therapy (ACT) in Patient with Cardiovascular Disease: A Systematic Review.",
        "abstract": "bBackgroundObjectivesb Cardiovascular disease CVDs encompass wide range heart vascular condition remain leading cause death worldwide Acceptance Commitment Therapy ACT psychotherapeutic approach integrates acceptance mindfulness commitment valuebased actions systematic review aim explore current evidence potential role ACT intervention supporting psychological wellbeing among individual CVDs bMethodsb systematic review conducted accordance PRISMA guidelines search literature conducted Scopus PubMed Web Science Cochrane PsycINFO databases Six study met inclusion criteria bResultsb reviewed study suggest ACT may promote psychological flexibility emotion regulation selfcare behavior patient CVDs Reported outcome include improved mindfulness reduced distress enhanced quality life However evidence base limited size methodological rigor included study varying design population bConclusionsb preliminary finding indicate ACT show promise addressing psychological aspect CVDs current evidence remains insufficient draw definitive conclusions highquality largescale study needed evaluate effectiveness clinical applicability ACT cardiovascular populations",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40805864/",
        "source_type": "Global"
    },
    {
        "pmid": "40805859",
        "title": "Evaluation of Pre-Treatment Assessment of Semaglutide Users: Balancing the Benefits of Weight Loss vs. Potential Health Consequences.",
        "abstract": "bBackgroundb Although semaglutide Ozempicsup®sup prescribed offlabel individual obesity concern arisen regarding use particularly regarding risk thyroid pancreatic disorders Therefore crucial screen patients medical family disease histories well certain clinical parameters initiating treatment obesity weight management However limited research investigating whether pretreatment assessment adopted clinical practice bMethodb singlecenter retrospective study involving adult prescribed semaglutide obesity weight management Demographic data comorbid conditions semaglutiderelated lab work disease history assessments including pancreatitis thyroid abnormalities oculopathy neuropathy family history thyroid cancer evaluated documented prior treatment initiation bResultsb total 715 patient included study average age 402 ± 120 years 495 participant male average weight BMI prior using semaglutide 998 ± 181 kg 363 ± 83 kgmsup2sup respectively predominantly overweight obese individual collectively 913 Approximately 69 patient 35 complications high prevalence cardiovascular metabolic disease using semaglutide Although HbA1c serum creatinine TSH T3 T4 triglycerides HDL LDL total cholesterol total bilirubin monitored prior semaglutide use none patients pancreatic lipase amylase calcitonin level measured Although important investigate personal family disease histories including thyroid abnormalities thyroid cancer pancreatitis retinopathy eye problems neuropathy prior semaglutide initiation check conducted 18 patients despite 986 least one disease assessed pretreatment bConclusionsb current pretreatment assessment approach patient prescribed semaglutide weight reduction underdeveloped particularly regard assessing influence disease history semaglutide use predisposes patient risk severe clinical outcomes including thyroid cancer pancreatitis retinopathy",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40805859/",
        "source_type": "Global"
    },
    {
        "pmid": "40804726",
        "title": "Fabry disease in females: organ involvement and clinical outcomes compared with the general population (103/150 characters).",
        "abstract": "Fabry disease FD rare Xlinked progressive multisystem disorder glycosphingolipid metabolism cause cellular organ damage multiple body systems FD studied extensively female male due greater heterogeneity presentation variability disease course females Furthermore despite published evidence contrary female still often referred carrier FD symptom assumed mild Findings recent study patient registry show twothirds female FD experience sign symptom different body systems third experiencing severe clinical manifestations Symptoms include wide variety cardiovascular neurologic kidney gastrointestinal psychiatricpsychologic effects significantly impair healthrelated quality life shorten life expectancy affected females Accurate timely diagnosis hindered overlap sign symptom which may nonspecific conditions well lack physician awareness Females FD often compared affected male counterpart opposed unaffected female general population may result less rigorous management female may appropriate contrasted males clinically appropriate consider onset severity symptom female FD comparison unaffected counterpart general population is therefore need greater representation female clinical study designed powered specifically detect endpoint group evaluate endpoint seen female general population without FD Improvements understanding disease phenotypes biomarkers presentation course outcome pediatric adult female needed",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40804726/",
        "source_type": "Global"
    },
    {
        "pmid": "40804626",
        "title": "Crosstalk between perivascular adipose tissue and adipocyte-derived peptide in the pathogenesis of diabetic cardiomyopathy.",
        "abstract": "Diabetic cardiomyopathy DCM prevalent complication diabetic patients pathogenic mechanism involves multiple endocrine metabolic factors dyslipidemia playing pivotal role pathogenesis disease Recent study highlighted importance peptide energy metabolism potential effect onset development DCM affecting function perivascular adipose tissue PVAT present review aim examine effect peptide perivascular adipose tissue myocardial metabolism pathogenesis DCM focusing role peptide distributed perivascular adipose tissue cardioprotection underlying mechanism action addition explore future research direction potential clinical application peptide treatment DCM",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40804626/",
        "source_type": "Global"
    },
    {
        "pmid": "40803921",
        "title": "A person-centred clinical approach to the multimorbid patient with COPD.",
        "abstract": "patient chronic disease multimorbid particularly important patient chronic obstructive pulmonary disease COPD average five identified comorbidities independently impact health increase mortality risk Using modified Delphi method selected 20 important disease associated COPD clustered five domains mental respiratory cardiovascular metabolic multiple organ loss tissue developed systematic approach characterise impact clinical presentation individual disease within cluster define priority timing measurement potential marker disease presence severity Given absence integrated guideline treat multimorbid patients reviewed selected individual disease guideline recommendation accessed specific information related management disease addition built multimorbidity Health Dashboard that completed patient health practitioner help identify presence severity comorbid diseases using practical comprehensive approach possible identify characterise important comorbid disease patient COPD implement management tool help improve outcome expert consensus commentary summarises patientcentred recommendation manage comorbidities COPD patients aiming improve qualityoflife reduce disease burden holistic approach Prospective pragmatic trial comparing approach usual care multimorbid patient COPD including longterm followup urgently needed",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803921/",
        "source_type": "Global"
    },
    {
        "pmid": "40803911",
        "title": "Novel therapies - IMID Co-morbidities.",
        "abstract": "Cardiovascular disease CVD metabolic syndrome common patient immunemediated inflammatory disease IMID condition exhibit significant interactions disease relation treatments highlighting need rheumatologist take active role management known inflammation mediated adipokines important pathogenesis obesity cardiovascularkidneymetabolic CKM syndrome Novel therapeutic developed metabolic comorbidities demonstrated pleiotropic benefit across range diseases even possess antiinflammatory immunomodulatory effects serving adjunct management IMID hand antiinflammatory drug rigorously tested efficacy CVD colchicine become first antiinflammatory drug approved purpose paper focus novel therapeutic new purpose conventional drug management CVD metabolic syndrome additional discussion relevance IMID",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803911/",
        "source_type": "Global"
    },
    {
        "pmid": "40803762",
        "title": "Relieving the Pressure: Evaluating the Coronary Sinus Reducer for Refractory Angina.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803762/",
        "source_type": "Global"
    },
    {
        "pmid": "40803758",
        "title": "Renal Denervation in Hypertension and Chronic Heart Failure.",
        "abstract": "Renal denervation RDN interventional approach target sympathetic nervous system goal modulating activity important contributor pathogenesis many cardiovascular metabolic diseases Unlike pharmacologic therapies RDN efficacy independent patient adherence medications remains major limiting factor longterm blood pressure control Initially developed treat severe treatmentresistant hypertension RDN demonstrated consistent result recent shamcontrolled trial across spectrum hypertension result RDN incorporated European guideline treatment option select patient endorsed cardiovascular hypertension society worldwide review outline physiological rationale behind RDN summarizes current evidence supporting effectiveness provides overview available technologies evaluates emerging role treatment chronic heart failure condition characterized high sympathetic nervous system activity Finally author explore future directions including concept multiorgan denervation aim achieve enhanced degree sympathetic modulation targeting additional sympathetic nerve beyond kidney",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803758/",
        "source_type": "Global"
    },
    {
        "pmid": "40803217",
        "title": "JNK in inflammation and lipid metabolism regulation in atherosclerosis.",
        "abstract": "Atherosclerosis systemic arterial disease characterized lipid deposition chronic inflammation endothelial dysfunction driven complex multifactorial regulation cJun Nterminal kinase JNK key member stressactivated mitogenactivated protein kinase family play central role pathogenesis JNK regulates oxidative stress lipid metabolism inflammation mediating interaction cell organs example vascular injury activates JNK triggering downstream pathway amplify inflammation accelerate disease progression JNK also indirectly influence vascular health modulating metabolic inflammatory process organ liver kidneys underscoring interorgan synergy review highlight potential JNK therapeutic target atherosclerosis Understanding pathway may help develop effective treatment complex systemic disease",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803217/",
        "source_type": "Global"
    },
    {
        "pmid": "40803202",
        "title": "Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases.",
        "abstract": "Diabetes related metabolic disease high prevalence increasing incidence create significant socioeconomic burden contribution global mortality disabilityadjusted life years According data Global Burden Disease Study high fasting plasma glucose high total cholesterol rank third fourth list global health risk factors behind high blood pressure smoking Diabetes adversely affect endothelial cardiac function thereby contributing significantly development progression cardiovascular diseases represents leading health risk factor cause death worldwide Oxidative stress inflammation play key role pathophysiology underlying diabetes mellitus associated cardiometabolic complications metabolic dysfunctionassociated fatty liver disease hypertension atherosclerosis myocardial ischemiareperfusion heart failure Here highlight beneficial effect modern antidiabetic drug class dipeptidyl peptidase 4 inhibitors glucagonlike peptide 1 receptor agonists sodiumglucose cotransporter 2 inhibitor overall cardiovascular mortality diabetic individuals particular emphasis effect oxidative stress inflammation endothelial dysfunction discus mechanism action pleiotropic beneficial effect compare standard diabetic cardiovascular therapy SIGNIFICANCE STATEMENT Modern antidiabetic drug confer organ protection go beyond simple glucoselowering SGLT2 inhibitor incretinbased drug possess direct reno vasculo cardioprotective effect based potent antioxidant antiinflammatory properties pleiotropic effect comprise improved lipid handling weight loss prevention thrombosis ischemic heart damage beneficial regulation nitric oxide signaling epigenetic microbiotic pathways",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40803202/",
        "source_type": "Global"
    },
    {
        "pmid": "40802996",
        "title": "Enzyme-Responsive Peptide-Prodrug Integrated Biphasic Microneedle Patch for Enhanced Transdermal Delivery and Hypertension Therapy.",
        "abstract": "Hypertension major risk factor cardiovascular disease need effective blood pressure reduction Current antihypertensive drugs captopril face challenges including enzymatic degradation liver firstpass effect Here developed dissolving microneedle MN loaded peptidebased enzymeresponsive prodrug peptidecaptopril PC enhance stability captopril enable efficient transdermal delivery Kinetic study revealed PC exhibited lower iKisubmsub value 11 × 10sup5sup M esterasemediated hydrolysis compared free captopril 21 × 10sup5sup M indicating improved enzymatic stability Meanwhile PC encapsulated stably microneedle tip form PC MN achieving approximately 90 transdermal drug delivery spontaneously hypertensive rat models PC MN elicited rapid potent bloodpressurelowering effect outperforming oral captopril administration study present promising selfadministering strategy enhance hypertension treatment efficient transdermal drug delivery",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802996/",
        "source_type": "Global"
    },
    {
        "pmid": "40802984",
        "title": "CROI 2025: Metabolic and Other Complications of HIV Infection.",
        "abstract": "Agingrelated comorbid condition major effect health quality life survival people HIV PWH 2025 Conference Retroviruses Opportunistic Infections CROI featured numerous study comorbid disease PWH Cardiovascular diseases including atherosclerosis heart failure important topic CROI ancillary analysis REPRIEVE the Randomized Trial Prevent Vascular Events HIV study lower middleincome countries Numerous study examined epigenetic marker biologic aging PWH effect treatments including glucagonlike peptide1 receptor agonists clinical trial cytomegalovirus suppression shown decrease immune activation systemic inflammation well improve physical function Large epidemiologic study examining effect switching integrase strand transfer inhibitor showed increased risk diabetes hypertension independent weight gain review focus abstract presented CROI 2025 areas highlighting clinical impact",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802984/",
        "source_type": "Global"
    },
    {
        "pmid": "40802021",
        "title": "Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand.",
        "abstract": "Renal denervation RDN introduced novel nonpharmacological intervention patient hypertension poorly controlled pharmacological means study aim evaluate costeffectiveness Netrod RDN treatment plus antihypertensive compared antihypertensive alone hypertension Mainland China Japan Thailand Markov decisionanalytic model developed simulate longterm clinical events qualityadjusted life year QALYs related cost among patient underwent RDN regimen antihypertensive regimen line NetrodHTN trial yearly cycle 30year horizon study adopted perspective healthcare systems Cost utility input collected published literature price databases expert consultations hospital information systems cost outcome discounted rate 5 Model validation univariate probabilistic sensitivity analyses scenario analysis conducted verify robustness results Compared antihypertensive regimen alone RDN regimen yielded 3061 reduction cardiovascular cerebral renal events Costeffectiveness analysis showed RDN regimen yielded favorable incremental costeffectiveness ratio Japan 3451 per QALY followed Thailand 13932 per QALY Mainland China 19049 per QALY Sensitivity scenario analysis confirmed robustness findings Netrod RDN costeffective intervention healthcare system perspective Mainland China Japan Thailand However costeffectiveness varies across countries reflecting difference socioeconomic contexts middle lowincome countries appropriate pricing strategy may play key role enhancing affordability costeffectiveness",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40802021/",
        "source_type": "Global"
    },
    {
        "pmid": "40801957",
        "title": "Polygenic Modulation of Monogenic Diseases: Familial Hypercholesterolemia as the Exemplar.",
        "abstract": "Heterozygous Familial Hypercholesterolemia HeFH among common genetic condition worldwide affect  1 300 individuals HeFH characterized increased level lowdensity lipoprotein cholesterol LDLC increased risk coronary artery disease CAD wide spectrum severity within HeFH population variability expression incompletely explained known risk factors purpose review discus recent study examined polygenic risk modulate phenotypic expression HeFH past several years polygenic risk score PRS summarize information many genetic variant influence various trait developed includes polygenic risk score level LDLC lipid fractions CAD various cardiometabolic traits individual clinical phenotype compatible HeFH pathogenic variant present elevated PRS LDLC may explain hypercholesterolemia Among individual monogenic HeFH elevated PRS LDLC CAD exacerbate clinical phenotype increase risk cardiovascular events Conversely low PRS trait mask presentation HeFH decreasing clinical severity thus lead incomplete phenotypic penetrance pathogenic HeFHcausing variant Although HeFH prototypical monogenic condition recent study revealed genomic background reflected PRSs modulate clinical phenotype severity thus adding previously unrecognized level complexity monogenic disease identified PRSs alter clinical trajectory HeFH next challenge field implement PRS testing clinical practice allow clinician tailor risk prediction treatment approach based individuals unique complement genetic factors",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40801957/",
        "source_type": "Global"
    },
    {
        "pmid": "40801869",
        "title": "Pressure-Volume Analysis Demonstrates Short- and Long-Term Hemodynamic Effects of Atrioventricular Interval Modulation Therapy in Hypertension.",
        "abstract": "Prior study show atrioventricular interval modulation AVIM therapy provides immediate substantial sustained clinically meaningful reduction ambulatory office systolic blood pressure SBPs hypertensive patient pacemakers goal study assess acute chronic mechanism AVIM therapy reduces blood pressure assess impact lead location mechanisms Acute hemodynamic effect assessed invasive pressurevolume PV analysis hypertensive subject N  16 intact atrioventricular AV conduction impact standard right ventricular pacing RVp v left bundle branch area pacing LBBAp also evaluated Chronic effect AVIM therapy assessed using noninvasive PV analysis data subgroup subject n  32 MODERATO II study NCT02837445 Acutely studied subject average office SBP 144 ± 25 mm Hg despite antihypertensive medications AVIM therapy significantly reduced enddiastolic volume 126 ± 140 mL RVp P  0003 186 ± 162 mL LBBAp P  0001 effective arterial elastance 023 ± 039 mm HgmL RVp P  0032 031 ± 055 mm HgmL LBBAp P  0037 leading significant SBP reduction 171 ± 101 mm Hg RVp P  0001 192 ± 126 mm Hg LBBAp P  0001 Neither left ventricular LV endsystolic enddiastolic property significantly affected AVIM therapy either pacing site Noninvasive PV analysis showed similar reduction SBP 117 ± 218 mm Hg P  0023 reduction enddiastolic volume 215 ± 192 mL P  0005 v control indicative reverse remodeling AVIM therapy acutely reduces SBP decreasing preload effective arterial elastance unrelated lead location without affecting LV endsystolic enddiastolic function Chronic AVIM therapy reduces SBP enddiastolic volume indicative favorable reverse LV remodeling",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40801869/",
        "source_type": "Global"
    },
    {
        "pmid": "40801823",
        "title": "The Synergistic Treatment of Heart and Kidney Disease.",
        "abstract": "incidence prevalence cardiac renal disease Germany steadily rising Heart disease common cause death especially among people chronic kidney disease Impaired kidney function increase risk cardiovascular events vice versa narrative review based pertinent publication retrieved literature search year 2025 particular attention guideline Association Scientific Medical Societies Germany Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften AWMF European Society Cardiology ESC Supplementary search conducted individual aspect epidemiology diagnosis treatment heart kidney disease heart kidney closely pathophysiologically linked damaged shared vascular risk factors including diabetes mellitus arterial hypertension chronic inflammation shared mechanism give rise continuum diseases Multiple RCTs shown recent year morbidity mortality patient heart kidney disease significantly lowered treatment ACE inhibitors also sodiumglucose cotransporter 2 SGLT2 inhibitors glucagonlike peptide 1 receptor agonist GLP1RA nonsteroidal mineralocorticoid receptor antagonist nsMRA Absolute risk reduction range 18 67 found achievable combined endpoint studied depending particular active substance used Heart kidney disease often arise together treated new pharmacotherapeutic strategies Open question remain concerning potential synergistic effect drug mentioned above suitable management polypharmacy enabling costeffective care",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40801823/",
        "source_type": "Global"
    },
    {
        "pmid": "40801813",
        "title": "<i>Streptomyces</i> sp. BI87 from human gut: potent anticancer activities and divergence from known <i>Streptomyces</i> lineages.",
        "abstract": "Cancer among deadliest disease truly curative therapies Recent study shown human intestinal microbiota contains bacteria exhibit potent suppressive effect cancer coordinate anticancer function immune system However whether peculiar anticancer trait acquired stochastically strain nonanticancer bacterial specie intrinsic property phylogenetic lineage bacteria remained unclear study compared human gut isolate iStreptomycesi sp BI87 highly effective anticancer activities type strain iStreptomyces albidoflavusi DSM 40455supTsup closely related BI87 among 30 type strain genus iStreptomycesi show detectable anticancer activities found that although BI87 DSM 40455supTsup 99 16S rDNA sequence similarity phylogenetically separated genetic boundary distinct natural specie evaluated 3Cs definition bacterial specie based ratio common gene zero sequence degeneracy addition anticancer activities BI87 encodes several biological characteristic different DSM 40455supTsup including antibacterial antiviral spectra secondary metabolites structural composition cell wall major cellular fatty acids Based genomic phenotypic distinction BI87 closely related iStreptomycesi strains propose anticancer bacterial strain BI87 represents new lineage natural specie level within genus iStreptomycesiIMPORTANCEThe characterization anticancer bacterial strain iStreptomyces spi BI87 isolated healthy human suggests prevalent existence anticancer microbe gut microbiome humans may nurtured harnessed cancer prevention treatment without need introduction engineered nonindigenous microbe person use radio chemotherapies Also important finding close relative BI87 iStreptomyces albidoflavusi DSM40455supTsup express appreciable anticancer property iin vitroi iin vivoi experiments demonstrating iStreptomycesi sp BI87 represents novel bacterial lineage selective suppressive activity cancer phylogenetic level natural species Genomic comparison BI87 DSM40455supTsup demonstrate phylogenetic delineation closely related bacteria need conducted level natural specie rather OTUs OTU may contain phenotypically even phylogenetically radically distinct bacteria",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40801813/",
        "source_type": "Global"
    },
    {
        "pmid": "40801775",
        "title": "Pressure injuries in patients receiving extracorporeal membrane oxygenation: a tertiary centre experience.",
        "abstract": "Pressure injury PIs common patient receiving intensive care extracorporeal membrane oxygenation ECMO study assessed incidence risk factor PIs patient receiving ECMO COVID19associated acute respiratory distress syndrome ARDS Patients admitted intensive care unit ICU severe COVID19associated ARDS received venovenous ECMO April 2020 January 2022 evaluated patient monitored evaluated managed according iPrevention treatment pressure ulcers clinical practice guideline 2019i risk PI evaluated using Braden scale Staging PIs made according National Pressure Injury Advisory Panel guidelines total 78 patient median age 45 years received ICU care ECMO support these 75 patient transferred ICU ECMO support 2478 308 patient already PIs New PIs developed 24 patient 2454 444 prolonged period ECMO median 485 days new PIs mainly stage 2 55 median time new PI development ECMO 21 range 460 days mortality rate 3254 593 multivariable analysis age odds ratio OR 1103 95 confidence interval CI 1022 1191 p0027 ECMO duration OR 1048 95 CI 1016 1081 p0003 independent predictor PI development Strict compliance clinical practice guideline PIs dedicated ICU team may considerably reduce incidence PIs among patient receiving ECMO prolonged periods",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40801775/",
        "source_type": "Global"
    },
    {
        "pmid": "40801610",
        "title": "Essential Pieces of the Puzzle: The Roles of VEGF and Dopamine in Aging.",
        "abstract": "Aging wellknown complex physiological process characterized progressive functional decline increased susceptibility disease particularly cardiovascular nervous systems genetic environmental factor shape advancement molecular regulator vascular endothelial growth factor VEGF dopamine signaling emerged critical factor maintaining vascular neural health VEGF promotes angiogenesis tissue repair dopamine primarily recognized neuromodulatory roles regulates vascular tone appears modulate VEGF activity Despite substantial research role cardiovascular neurodegenerative diseases little known VEGF dopamine interact aging process particularly healthy versus unhealthy aging contexts review describes existing evidence independent potentially complementary role VEGF dopamine aging emphasizing influence maintaining improving neurovascular health also explores lifestyle intervention may beneficial modulating VEGF dopamine signaling pathway aging population addressing current knowledge gap surrounding VEGFdopamine crosstalk review highlight need investigation combined effect targeting molecular interaction unlock new research avenue innovative strategy healthy aging potential treatment agerelated diseases",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40801610/",
        "source_type": "Global"
    },
    {
        "pmid": "40801324",
        "title": "Potential benefits of vitamin D on brain pathologies and cognitive function in metabolic syndrome: evidence from <i>in vivo</i> and clinical studies.",
        "abstract": "Metabolic syndrome MetS global health issue linked cardiovascular diseases type 2 diabetes mellitus cognitive impairment Chronic inflammation oxidative stress associated MetS condition contribute cognitive decline highlighting need therapeutic strategy mitigate complications Vitamin D fatsoluble vitamin play crucial role physiological functions Recent research highlighted neuroprotective role vitamin several pathological conditions Therefore review aim summarize discus evidence iin vivoi clinical study effect vitamin brain pathology cognitive function context MetS condition searched article published English PubMed Central January 2000 December 2023 using following keywords 1 vitamin D metabolic syndrome brain 2 vitamin D metabolic syndrome cognition 3 vitamin D obesity cognition 4 vitamin D obesity brain 5 vitamin D hyperglycemia brain 6 vitamin D dyslipidemia brain 7 vitamin D T2DM brain 8 vitamin D T2DM cognition Vitamin treatment animal MetS condition attenuated metabolic disturbance including inflammation oxidation hyperglycemia obesity insulin resistance ameliorated cognitive dysfunction suggesting beneficial effect vitamin MetS condition evidence indicates vitamin may potential therapeutic option reduce cognitive dysfunction caused metabolic syndrome",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40801324/",
        "source_type": "Global"
    },
    {
        "pmid": "40801109",
        "title": "Safety of endovascular therapy in ischemic stroke patients ⩾90 years: A cohort study from the EVA-TRISP collaboration.",
        "abstract": "Data safety endovascular therapy EVT elderly scarce Using data large prospective EVT registry aimed providing better evidence EVT decisionmaking patient aged 90 year older multicentre observational study EVATRISP collaboration outcome compared patient aged ⩾90 year aged 90 year using multivariate logistic regression analysis reporting odds ratio 95 confidence intervals Outcomes occurrence poor functional outcome survivor modified Rankin Scale mRS 35 prestroke mRS 02 mRS higher prestroke mRS prestroke mRS 35 mortality 3 month stroke unsuccessful recanalization mTICI 02a symptomatic intracranial hemorrhage sICH defined ECASSIIIIIcriteria 13306 eligible patients 892 ⩾90 year old 67 elderly higher median National Institutes Health Stroke Scale NIHSS admission 16 v 14 likely prestroke mRS 35 380 v 87 odds poor functional outcome ORsubadjustedsub 235 95CI 187297 616 v 387 death ORsubadjustedsub 304 95CI 260355 539 v 213 unsuccessful recanalization ORsubadjustedsub 134 95CI 114157 324 v 272 higher patient aged ⩾90 years odds sICH differ ORsubadjustedsub 092 95CI 066128 51 v 50 EVTtreated stroke patient ⩾90 year higher odds poor functional outcome mortality unsuccessful recanalization younger patients However probability sICH EVT increased decision favor EVT elderly based age alone",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40801109/",
        "source_type": "Global"
    },
    {
        "pmid": "40800084",
        "title": "Advances in erectile dysfunction treatment research: a narrative review.",
        "abstract": "Erectile dysfunction ED one common disease middleaged older men etiology mainly includes vascular diseases neurological diseases metabolic disorders psychological factors review take physiological mechanism penile erection starting point provides indepth look major current treatments include phosphodiesterase type 5 PDE5 inhibitors gene therapy techniques lowintensity extracorporeal shock wave therapy LiESWT lowintensity pulsed ultrasound therapy LIPUS psychological treatments review provides critical analysis summary advantage limitation associated treatment approach Finally article discusses future direction ED treatment emphasizing importance integrating personalized precision medicine principle treatment planning identify appropriate therapeutic strategy patient conducted literature search academic platform PubMed Google Scholar Web Science using term erectile dysfunction stem cells lowintensity extracorporeal shock wave lowintensity pulsed ultrasound PDE5 inhibitors gene therapy penile prosthesis implantation psychosexual therapy collecting literature published January 1990 October 2024 incidence ED showing trend becoming widespread affecting younger people identified main risk factor cause ED include psychological disorders hypertension cardiovascular disease CVDs unhealthy lifestyles basis study comprehensively review latest research progress traditional treatment method emerging treatment approaches analyzes respective advantage limitations ED treatment technology continue advance erectile function numerous patient seen significant improvement Looking future development trend combined treatment expected become mainstream strategy treating ED treatment method condition gradually move towards personalization precision",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40800084/",
        "source_type": "Global"
    },
    {
        "pmid": "40799637",
        "title": "Editorial: Translational advances in cardiovascular therapy: from bench to bedside.",
        "abstract": "",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40799637/",
        "source_type": "Global"
    },
    {
        "pmid": "40798971",
        "title": "Umbilical Cord Mesenchymal Stem Cells as a Meritorious Option to Treat Psoriasis.",
        "abstract": "Psoriasis chronic immunemediated disease affect significant percentage global population pathogenesis psoriasis involves rapid turnover skin cell immune system dysregulation particularly cellmediated autoimmune response Conventional treatment Psoriasis include topical therapy light therapy phototherapy systemic medications however limitation diverse side effect mentioned usage Therefore increasing attention directed toward finding alternative therapeutic method psoriasis Recently Umbilical Cord Mesenchymal Stem Cells UCMSCs gained attention potential treating various diseases including autoimmune disorders cardiovascular conditions metabolic disorders Multiple advantage reported UCMSCs including noninvasive collection low immunogenicity minimal ethical issues aim review explore potential UCMSCs treatment psoriasis",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40798971/",
        "source_type": "Global"
    },
    {
        "pmid": "40798959",
        "title": "The Cathepsin Family in Disease: From Molecular Mechanisms to Therapeutic Applications.",
        "abstract": "cathepsin family proteolytic enzyme involved maintenance major physiological processes including protein degradation immune modulation tissue remodeling apoptosis Members cathepsin family include cysteine serine aspartic proteases implicated diverse cellular functions Evidence tissuespecific expression emphasizes specialized function enzyme many organs However dysregulated cathepsin activity implicated wide range pathological conditions including limited to cancer cardiovascular diseases neurodegeneration autoimmune disorders significant therapeutic potential intervention whereby specific inhibitor certain cathepsins may offer promising strategy disease management Despite promise major challenge persist designing inhibitor avoid offtarget effect respecting dual physiological pathological role cathepsins Structural similarity among family member contextdependent function complicate precision targeting review identifies emerging strategiesincluding structureguided design cathepsincleavable delivery systems realtime imagingthat reshaping therapeutic approach toward complex enzymes structured webbased literature search conducted using PubMed Scopus Google Scholar employing keywords cathepsins therapeutic targeting proteolytic enzymes disease pathways inform review cathepsins continue play key role health disease much research warranted determine full therapeutic potential would represent foundation treatment option various complex diseases",
        "mesh_terms": [],
        "source": "https://pubmed.ncbi.nlm.nih.gov/40798959/",
        "source_type": "Global"
    }
]